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1  INTRODUCTION 
 
Cancer is a global problem, claiming the lives of over 8 million people in the year 2012 
alone (Ferlay et al. 2015). Furthermore, as the global population continues to grow and 
age, the number of new diagnoses is estimated to rise from approximately 14 million in 
2012 to 20 million by the year 2025 (Bray 2014; Ferlay et al. 2015). Translating these 
statistics to Finland, the National Institute for Health and Welfare assessed in 2013 that 
around a third of the population will develop cancer at some point during their lifetime 
(Vartiainen et al. 2013). The same year, the Finnish Cancer Registry (2017) reported over 
32,000 new diagnosed cancer cases, a number which is estimated to exceed 40,000 by the 
year 2025. Aside from the devastation cancer afflicts on the life of the people affected, 
whether patient or family member, the global economic impact of cancer is estimated to 
have amounted to US$ 1.16 trillion in the year 2010 alone (Knaul et al. 2014). 
 
Despite diligent cancer research and development of new treatments, much is still 
unknown about these maladies. Many cancers can be cured if diagnosed early and treated 
properly, and 30-50% of cancers are preventable with the help of prevention strategies 
and the avoidance of risk factors (World Health Organization 2017). There are even 
vaccines that can be utilized that protect people from carcinogenic infections. Over 2 
million of the 14 million newly diagnosed cancer patients in 2012 were due to infectious 
agents such as human papilloma virus, hepatitis B virus, and Helicobacter pylori bacteria 
(Plummer et al. 2016).  
 
Currently, cancer treatments are designed individually for each patient by a 
multidisciplinary team that plan the best treatment based on relevant factors, including 
the type of cancer, stage of progression, molecular markers, and other preexisting 
conditions. A fundamental aspect in the treatment strategy is to consider whether the aim 
is to cure the patient, manage the disease, prevent relapse, or alleviate the symptoms. 
Surgery, chemotherapeutics, and radiation therapy have long been pillars in cancer 
treatment with immunotherapy potentially emerging as a fourth (Farkona et al. 2016). 
Immunotherapy relies on immune system activation in the patient to treat the disease, a 
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few of the strategies employed including cytokines, immune checkpoint inhibition, cell-
based therapies such as vaccines, and different combination therapies.  
 
An interesting field in immunotherapy is oncolytic viruses (OVs) which are viruses with 
a natural or genetically modified propensity to selectively proliferate in tumor cells 
(Kaufman et al. 2015). There are several viruses that can be harnessed for this purpose, 
one being the adenovirus (Ad). The first reported observations of natural virus infection 
coinciding with tumor regression date back to the mid-1800s (Kelly & Russell 2007).  
Based on the many case reports that have accumulated since then, one of the conclusions 
that have been drawn is that there are circumstances in which certain viruses can destroy 
tumors without excessive harm to the patient. Aside from lysing tumor cells, the OVs can 
also be utilized as gene vectors of immunostimulatory compounds, thereby further 
promoting the elicitation of an immune system response and, ideally, systemic antitumor 
immunity.   
 
The first OV treatment was approved by the China's State Food and Drug Administration 
in the year 2005 (Garber 2006). Since then, the oncolytic adenovirus (OAd) H101 has 
been used for the treatment of head and neck cancer, albeit only in China. In late 2015, 
the herpesvirus talimogene laherparepvec (T-Vec) became the first oncolytic virus 
treatment approved by the Food and Drug Administration and the European Medicines 
Agency (EMA press release 2015; FDA press announcement 2015). With several other 
treatments at various stages of the development pipeline, the H101 and T-Vec are 
hopefully only the beginning for OVs.  
 
This work aims to delve into OV based therapies in oncology and the potential they 
provide in finding a cure for cancer. After briefly examining cancer on a global scale as 
well as addressing characteristics and challenges related to the diseases, the field of 
oncolytic immunotherapy is explored regarding the adenovirus (Ad) and the advantages 
and disadvantages it brings. Finally, a protocol is conceived for the generation of a 
genetically armed OAd, from cloning until primary virus production. 
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2  CANCER 
 
Cancer is a hypernym used to describe the more than 100 diseases that can develop in 
almost any part of the human body (Stratton et al. 2009). These diseases have varying 
risk factors and epidemiology but share one characteristic which is the uncontrolled 
growth of abnormal cells. The evolution of different cancers is the product of repetitive 
clonal expansion, positive selection, and genetic diversification in the tissue the cancer 
develops (Greaves & Maley 2012). This process of tumor development is referred to as 
oncogenesis. 
 
Two central terms in oncology are tumor and cancer. The meaning of these words lacks 
certain consistency as they are at times used interchangeably to describe all forms of 
abnormal tissue growths (neoplasms). The term tumor usually encompasses both benign 
and malignant neoplasms, whereas cancer is generally reserved for malignant neoplasms. 
The morphological differentiation can at times be difficult, but generally benign tumor 
cells proliferate into one discernable tumor mass contained to one area. In contrast, 
malignant tumor cells invade surrounding tissues with the potential of spreading to other 
parts of the body by dislodging clusters of cells. These clusters are capable of forming 
new tumors referred to as metastases. If unhindered, malignant tumors will expand 
aggressively and continue to spawn metastases, thereby increasing the tumor burden. In 
90% of cancer cases, metastases are the main cause for morbidity and mortality (Monteiro 
& Fodde 2010).  
 
2.1 The Cancer Genome  
 
Cancer is a genetic disease that develops progressively through genetic alterations to the 
cell genome (Hanahan & Weinberg 2000). The encompassing notion is that cancer is the 
product of Darwinian evolution between cell populations in a microenvironment (Stratton 
et al. 2009). This evolutionary process is based upon the acquisition of heritable genetic 
variation among individual cells by essentially random mutation and the natural selection 
among the different phenotypes that develop as a result.  
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The alterations found in a cancer genome have accumulated over the lifetime of the 
patient (Stratton et al. 2009). DNA damage can arise spontaneously or as the result of 
endogenous or exogenous agents known as mutagens (Stratton et al. 2009; Helleday et 
al. 2014). Endogenous mutagens can originate from normal metabolic processes, whereas 
exogenous mutagens stem from either physical or chemical environmental sources 
(Helleday et al. 2014). Examples of exogenous mutagens include non-ionizing ultraviolet 
(UV) radiation, asbestos, and tobacco smoke. DNA damage and replication errors are 
generally dealt with by repair mechanisms in the cell. However, should the damage go 
undetected or be repaired erroneously, the mutations will become permanent (Stratton et 
al. 2009). Mutagenic or non-mutagenic agents that increase the risk of developing cancer 
by damaging cells are referred to as carcinogens.   
 
The mutations observed in the cancer genome can be divided into germ line and somatic 
mutations. Germ line mutations are inherited from the parent cell whereas somatic 
mutations are acquired independently over the lifespan of the cell (Stratton et al. 2009). 
Depending on their significance in oncogenesis, somatic mutations can be further 
classified as either driver or passenger mutations. Of these two, the driver mutations 
actively contribute to disease development whereas passenger mutations fail to confer 
any growth advantage. Driver mutations reside in cancer genes, bestowing a growth 
advantage for the cell that causes their positive selection during cancer development.  
 
The metamorphosis undergone by a cancer cell reflects the dynamic alterations whereby 
the regulatory circuits that normally control cell proliferation and homeostasis become 
defective (Hanahan & Weinberg 2000). On average, common solid tumors of colon, 
breast, brain, and pancreas origin have 33-66 genes with slight somatic mutations that 
cause changes in the produced proteins (Vogelstein et al. 2013). The number of mutations 
does, however, vary between different cancer types, with melanomas and lung tumors 
having circa (ca) 200 mutations that alter the nucleotide encoded amino acid sequences. 
The high frequency is a testament to the potency of the mutagens involved, i.e. ultraviolet 
light in melanoma and tobacco smoke in lung cancer.  
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There are certain common mutagenic targets for several cancer types that increase cancer 
promoting gene (oncogene) expression and reduce tumor inhibiting gene (tumor 
suppressor gene) expression. An estimated 90% of somatically mutated cancer genes 
behave dominantly and thus aid in cancer development even when present in only one 
allele (Stratton et al. 2009). The remaining 10% of the genes that act recessively generally 
cancel protein production upon expression and are alternatively referred to as tumor 
suppressor genes. Two intensely studied tumor suppressors that are common mutagenic 
targets in cancer are the retinoblastoma (Rb) gene family and the p53 gene.  
 
The Rb receives its name from the cancer retinoblastoma from which the first tumor 
suppressor gene Rb1 was identified (Lapenna & Giordano 2009). Nonetheless, the loss 
of Rb protein occurs in several other cancers as well (Sherr & McCormick 2002). The 
encoded proteins of the Rb family are important regulators of cell proliferation, for 
example participating in the inhibition of transition from the G1 phase to the S phase of 
the cell cycle where DNA replication occurs (Lapenna & Giordano 2009). Consequently, 
the deregulation of the Rb pathway by gene inactivation promotes proliferation of cancer 
cells. 
 
The p53 gene encodes for a transcription factor of the same name, which is activated in 
the event of DNA damage, hypoxia, and oncogene activation (Sherr & McCormick 2002). 
The p53 transcription factor can regulate gene expression that either blocks the cell cycle 
from continuing or induces apoptosis. Mutations of p53 can be found in over 50% of 
human cancers (Kaufman et al. 2015). In the remaining cancers with normal p53 gene 
activity the genes affecting its function are generally mutated  
  
In contrast to the aforementioned tumor suppressor genes, the Ras gene family has been 
found to be subject to mutagenic activation in cancer. The family consists of N-, H-, and 
K-Ras which are small guanosine triphosphatases (Ancrile et al. 2008). The Ras proteins 
are important regulators of many crucial signaling pathways that control normal cellular 
proliferation (Downward 2003). Mutations in certain tumors target the Ras genes, thereby 
rendering the encoded Ras protein perpetually activated, stimulating growth and 
differentiation autonomously (Bos 1989). Even if the genes themselves are unaffected, 
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alterations in the components of the signaling pathways preceding or succeeding them 
cause aberrant Ras function to be found in the most human tumors (Downward 2003).   
 
The incidence of the highlighted mutations varies between different tumors and can 
present independently of each other. The impact these mutations have on oncogenesis and 
tumor growth make them attractive targets for certain cancer treatments. The approaches 
range from utilizing the aberrant function of the subsequent signaling pathways, or 
attempts to restore or replace the normal gene functions.   
 
2.2 The tumor microenvironment 
 
Normal tissue physiology is achieved and upheld by a strictly regulated balance between 
cell death and proliferation (Joyce & Pollard 2009). Different components of the 
microenvironment contribute to achieving and maintaining this homeostasis in various 
ways. In tumors, however, the microenvironment can become corrupt, promoting the 
survival and growth of tumor cells in favor of upholding normal tissue physiology. The 
subsequent milieu that develops is referred to as the tumor microenvironment (TME). 
The TME and the tumor cells share a symbiotic and dynamic relationship that develops 
early in malignancies and continues to evolve with the tumor (Turley et al. 2015). The 
TME affects tumor cell growth in many ways, such as metastatic dissemination and tumor 
cell survival and is therefore a target for some anticancer therapies.  
 
Despite the numerous differences between cancer types, certain shared characteristics 
have been identified. Hanahan and Weinberg compiled a list in the year 2000 that based 
on extensive literature review, presented six hallmarks for cancer; see Figure 1. These 
characteristics were introduced as: sustained growth signals, evasion of growth inhibitors, 
eluding apoptosis, infinite proliferation, continued angiogenesis, and tissue invasion as 
well as metastasis. Later in 2011, Hanahan and Weinberg expanded on the list to involve 
altered energy metabolism and immune evasion as emerging hallmarks, as well as 
presenting two enabling characteristics, namely genetic instability and tumor-promoting 
inflammation. The TME is an important aspect in the development of these traits, the 
different components often participating in several hallmarks.  
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Figure 1: The hallmarks of cancers. The image depicts the hallmarks (1-6), emerging 
hallmarks (7 and 8), and enabling characteristic (9 and 10) generally associated with 
cancer. Modified Figure 6 from Hanahan and Weinberg (2011).  
 
2.3  Components of the Tumor Microenvironment  
 
The TME is a heterogenous entity comprised of several components that provide a 
complex microenvironment that rivals and may even supersede the one found in normal 
tissues (Hanahan & Weinberg 2011; Pattabiraman & Weinberg 2014). The components 
vary in proportion between tumors of different origins and development, but can often be 
divided into non-cellular and cellular groups (Pattabiraman & Weinberg 2014).  
 
The major non-cellular component in the TME is the extracellular matrix (ECM) that in 
normal tissues is an important regulator of tissue homeostasis (Joyce & Pollard 2009; 
Pattabiraman & Weinberg 2014). The ECM fulfils several functions by, for example, 
providing architectural support and different signals for survival and differentiation 
(Joyce & Pollard 2009). The basic components of the ECM are water, proteins, and 
polysaccharides; however, the composition and topology of the ECM is unique for every 
tissue (Frantz et al. 2010). The singular structures are the result of a dynamic and 
reciprocal exchange between several cellular components, such as epithelial, fibroblast, 
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and endothelial elements, and is continuously remodeled enzymatically and non-
enzymatically.  
 
Because of age or disease, the activity of the remodeling enzyme can become deregulated 
and manifests as abnormal ECM dynamics (Lu et al. 2012). This aberrant remodeling can 
be divided into either the excessive degeneration or formation of ECM. In tumors, there 
is commonly a notable stiffening of the ECM compared to normal tissue, a characteristic 
that can be traced to ECM deposition and remodeling by fibroblasts as well as increased 
contractility of the epithelium (Frantz et al. 2010). The release of growth factors through 
ECM remodeling, enhances vascular permeability and fosters angiogenesis. The positive-
feedback loop that is generated by the subsequent interstitial tissue pressure, potentiates 
tumor growth and survival which ultimately promotes metastasis. Several of the 
hallmarks of cancer are influenced by the surrounding ECM (Pickup et al. 2014). 
 
The major cellular components of the TME can be divided into cells of bone marrow cell 
(mesenchymal) or blood cell (hematopoietic) lineages. The mesenchymal cell lineage 
originates from the mesenchymal stem cells that differentiate into many cell types that 
include adipocytes, fibroblasts, myocytes, pericytes, and osteoblasts (Turley et al. 2015). 
Normally, these cells contribute to maintaining tissue homeostasis and wound healing, 
functions that upon corruption by the tumor can evolve to become pro-tumorigenic.  
 
In tumors, the cells of the mesenchymal cell lineage have varying ways of contributing 
to the oncogenesis and continued survival of the tumor. The mesenchymal stem cells 
themselves possess immune regulating abilities that may contribute to the development 
of a tolerance promoting environment in the tumor, though this contribution still lacks 
unequivocal evidence (Turley et al. 2015). For the differentiated progenies of these stem 
cells, however, there are more studies implicating a stronger evidence-based connection 
between them and protumor activity. One of these cell types are the pericytes, which are 
stromal cells involved in angiogenesis and immune regulation.  
 
The cells of hematopoietic origin are further divided into two lineages: lymphoid and 
myeloid (Pattabiraman & Weinberg 2014). Cells types belonging to the lymphoid lineage 
include T and B lymphocytes and natural killer cells whereas cell types of the myeloid 
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lineage include macrophages and neutrophils. An additional cell type developing from 
both cell lines are the dendritic cells (DC). The different innate and adaptive immune cells 
can have dual roles in the tumor environment (Table 1). When anti- and protumor 
functions are a possibility, the action that prevails is largely dependent on the molecules 
being expressed as well as the abundance and activation state of various cell types 
(Grivennikov et al. 2010).  
 
Table 1: The role of different immune and inflammatory cells regarding antitumor 
immunity and protumor inflammation. Modified from Table 1 Grivennikov et al. 2010. 
 
There are two main groups of mature T cells, the division of which is based on whether 
they express γδ or αβ receptors (Grivennikov et al. 2010). The T cells in the αβ group are 
either cytotoxic (CTLs) or helper cells (Th cells) depending on their effector functions, 
with the Th cells being further divided into the subsets Th1, Th2, Th17, T regulatory, and 
natural killer T cells. Depending on which T cells are activated, their effect can either be 
tumor promoting or suppressive. Studies have implicated many T cell subsets in solid 
tumors to participate in tumor promotion, progression, or metastasis, such as CTLs, Th1 
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cells, and Th2 cells. It is difficult to evaluate the importance of immunity and 
inflammation in early oncogenesis but the most abundant immune cells in the TME are T 
cells and the tumor-associated macrophages. Macrophages and different subsets of T cells 
can function as tumor promoters and either by themselves or together contribute to tumor 
progression and metastasis (Pollard 2004; DeNardo et al. 2009; Pattabiraman & 
Weinberg 2014).  
 
2.4  Therapeutic Targets in in the Tumor Microenvironment 
 
The TME is able to influence treatment responses by modifying cancer cell sensitivity to 
e.g. chemotherapy as well as targeted agents (Chen et al. 2015; Sun 2015). The 
recognition of the impact of TME components on disease progression and successful 
treatment outcome have generated an interest in developing new treatments targeting the 
TME. The TME impacts tumor development by shaping tumor cell phenotypes through 
induction of stress responses and genomic instability (Marusyk et al. 2012).  
 
The stromal cells of the TME are as opposed to cancer cells generally genetically and 
epigenetically stable, thereby having a reduced risk for developing resistance (Chen et al. 
2015). Conventional therapies are known to contribute to acquired resistance and 
compromise treatment outcome by inducing alterations to the TME. As of such, it is 
necessary to consider the overall TME response in clinical interventions. Therapeutics 
targeting specific stromal compartments have been successfully implemented and include 
e.g. bevacizumab (angiogenesis inhibitor), letrozole (aromatase inhibitor), and nivolumab 
(immune checkpoint inhibitor) (Kenny et al. 2007; Chen et al. 2015).  
 
Aside from the stromal cells, there are several immunological targets in the TME. By 
targeting immunoregulatory pathways or by introducing immunostimulatory compounds, 
the balance can be shifted in favor of immune activation over tolerance. Should antitumor 
immunity successfully develop, this approach provides the benefit of systemic tumor 
eradication as well as lifelong protection against that particular tumor. Hence, 
immunotherapy currently holds some of the greatest expectations and potential in 
oncology. 
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3  ADENOVIRUSES  
 
Ads belong to the genus Mastadenovirus, one of the major lineages of the Adenoviridae 
family (Davison et al. 2003). To date, 57 serotypes are known to affect humans and these 
are further classified into seven species (A-G) as is depicted in Table 2 (Buckwalter et al. 
2012; Kaufman et al. 2015). The classification of the different serotypes depends on their 
characteristics regarding: serology, hemagglutination, oncogenic potential in rodents, 
genome sequence, and transformation of primary cells (Berk 2013). 
 
Table 2: The major sites of infection for different serotypes. Derived from Table 56.1 by 
Wold and Ison (2013). 
 
The Ad is a vertebrate virus that derives its name from adenoid from which it was first 
isolated (Rowe et al. 1953; Hilleman & Werner 1954). The virus is transmitted via 
aerosols and direct contact, generally causing mild self-limiting symptoms in 
immunocompetent individuals, e.g. keratoconjunctivitis and respiratory infections 
(Zhang & Bergelson 2005; Echavarría 2008; Kaufman et al. 2015). In children and 
immunocompromised individuals, adenoviral infections can cause severe conditions such 
as meningoencephalitis and pneumonia (Krilov 2005; Echavarría 2008).  
 
The Ad structure consists of a non-enveloped icosahedral capsid comprised mainly of the 
of proteins hexon, fiber, and penton (Law & Davidson 2005). The viral capsid measures 
around 90 nm in diameter, excluding the protrusions from the surface of the capsid that 
 
Species Serotype Respiratory Urinary 
Gastro-
intestinal 
Ocular 
A 12, 18, 31 X X X  
B 
3, 7, 11, 14, 16, 21, 34, 
35, 50, 55 
X X X X 
C 1, 2, 5, 6, 57 X X X  
D 
8, 9, 10, 13, 15, 17, 19, 
20, 22, 21, 23, 24, 25, 26, 
27, 28, 29, 30, 32, 33, 36, 
37, 38, 39, 42, 43, 44, 45, 
46, 47, 48, 49, 51, 53, 54, 
55, 56 
  X X 
E 4 X   X 
F 40, 41   X  
G 52   X  
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can be seen in Figure 2. These protrusions consist of fiber protein that are anchored to the 
hexon capsid by a pentameric penton base at the proximal end, while forming a globular 
domain at the distal end known as a knob (Zhang & Bergelson 2005). The capsid of the 
Ad encases a linear double-stranded DNA that is 26,000-45,000 bp in size (Davison et al. 
2003). 
 
 
 
 
 
 
 
 
 
 
Figure 2: The adenovirus ranges from ca 80 to 90 nm in diameter and is structurally 
comprised of a capsid enveloping a linear double-stranded DNA genome. The main 
capsid components are hexon, fiber, and penton (Giberson et al. 2012).  
 
The Ad5 consist of a ca 36,000 bp genome that encodes around 39 genes (Giberson et al. 
2012). The genome is sectioned into several transcription units that are expressed during 
the replication cycle that is generally divided into an early phase and a late phase (Berk 
2013). The early transcription units are identified as E1A, E1B, E2, E3, and E4 and the 
late transcription unit as one major late transcription unit further processed into late 
mRNAs L1-L5 through post-translational processing (Giacca & Zacchigna 2012). 
Additionally, four intermediate transcription units (IX, IVa2, L4 intermediate, and E2 
late) are transcribed at the beginning of viral DNA replication that marks the transition 
from early to late phase (Berk 2013). The transcription units of the Ad genome will be 
explored in further detail later in the chapter. The viral genome and the location of the 
different units are gathered in a simplified rendition (Figure 4) on the following page. 
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Figure 4: The Ad5 genome. Comprised of early (E1, E2, E3, and E4) and late transcription 
units (L1-L5) part of the major late transcription unit, the linear genome is flanked by 
inverted terminal repeats (ITRs) with a packaging signal (Ψ) on the left-hand side. 
Modified from Giberson et al. (2012) and Wold and Ison (2013). 
 
3.1  Infection of a host cell 
 
The Ad have a wide tissue tropism in the human body, as can be attested by Table 2 (page 
11). The species A, C, D, E, and F recognize and utilize the coxsackievirus and adenovirus 
receptor (CAR) for cell binding as part of cell entry (Roelvink et al. 1998). The CAR is 
a 46,000 Dalton transmembrane protein belonging to the immunoglobulin gene 
superfamily with two immunoglobulin-like extracellular domains expressed beneath tight 
junctions on the basolateral surface of polarized epithelial cells (Bergelson et al. 1997; 
Smith et al. 2010). Alternative ways for Ads to attach to cells include interactions with 
e.g. CD46, sialic acid, and integrins such as α3β1 (Salone et al. 2003; Smith et al. 2010) 
 
The host cell infection pathway may vary between different serotypes. However, Ad2 and 
Ad5 infections are generally two-part processes, beginning with primary receptor 
attachment followed by interaction with a secondary receptor that allows for the virus-
receptor complex to be internalized (Zhang & Bergelson 2005). For example, the Ad5 
binds to the primary receptor CAR with its fiber knobs which are a major means of 
attachment. Following receptor binding, the arginyl glycyl aspartic acid (RGD) contained 
in the penton base acts as the secondary recognition site for several cellular integrins. The 
RGD engagement of integrins induces activation signals for various proteins that are 
important for rearrangements in the actin cytoskeleton and the initiation of Ad 
internalization (Meier & Greber 2004; Zhang & Bergelson 2005).  
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The Ad enters the host cell in clathrin-coated vesicles, a process during which, in certain 
host cell types, the virus loses the fiber proteins during internalization in clathrin-coated 
pits (Meier & Greber 2004; Kremer & Nemerow 2015). Following vesicle maturation 
into endosomes, the capsid dissociation proceeds, allowing the release of amongst others 
the endosomolytic protein VI (Wiethoff et al. 2005). The protein is a minor capsid 
component that is released from its inner surface upon Ad uncoating and aids virus escape 
into the cytosol by mediating degeneration of the endosomal membrane. 
 
The journey to the nucleus of the partially uncoated virus occurs along microtubules 
following association with the dynein protein that recognizes either the hexon or protein 
VI (Kremer & Nemerow 2015). Upon reaching the nucleus, the Ad can deposit the genetic 
material by docking to a nuclear pore complex receptor (Meier & Greber 2004). Aiding 
in further uncoating the virus, the complex constitutes an entry point for the exposed viral 
genome that once inside the nucleus can undergo transcription and replication (Greber et 
al. 1997). The whole infection sequence is summarized in Figure 3.  
 
 
Figure 3: The cascade of Ad cell entry, uncoating, and the ultimate deliery of viral DNA 
into the nucleus. Modified from Meier and Greber (2004). 
 
3.2 Virus replication 
 
When the viral genome has successfully been delivered to the nucleus, the virus DNA 
transcription process can commence. During the early stage of the replication cycle, the 
translation of viral mRNA occurs alongside with host DNA (Berk 2013). However, as the 
infection progresses to the late phase, virtually all translation apparatuses of the host cell 
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exclusively process viral mRNA. The very first region to be transcribed is located in the 
E1A transcription unit (Nevins et al. 1979). The E1A region encodes gene products that 
activate transcription and participate in both entry into the S phase of cell cycle entry, as 
well as the generation of protective measures to elude antiviral defenses (Berk 2013). One 
central host cell mechanism affected by the expression of E1A regions are e.g. Rb family 
proteins.  
 
The E4 encoded proteins support successful virus replication by inducing altered cell 
signaling and account for disparate functions such as RNA splicing and translational 
regulation (Berk 2013). Similarly, the E1B transcription unit encodes products that serve 
to inhibit host cell antiviral response mechanisms. Two prominent proteins contribute to 
this goal by inhibiting apoptosis induced by the p53 protein, the activity and amount of 
which are elevated following the abnormal cell cycle entry promoted by the E1A. A 
generated complex between an E1B and E4 protein affect several proteins having 
detrimental functions to viral DNA replication by causing their proteasomal degradation; 
one of the affected proteins is the p53. Additionally, the complex is also necessary for 
e.g. nuclear export of viral late mRNAs and the inhibition of host mRNA nuclear export.   
 
To ensure the successful completion of the replication cycle of the virus, the antiviral 
response elements of the host are modulated by proteins encoded by the E3 transcription 
unit. Their expression aids the virus in avoiding detection by the immune system through 
regulation of host antiviral response elements (Hawkins et al. 2001; Giacca & Zacchigna 
2012). One such protein, the E3-gp19K, resides in the endoplasmic reticulum where it 
binds to the major histocompatibility complex class I (MHC-I) heavy chain, preventing 
transport of the complex to the cell surface and consequent detection and destruction by 
CTLs (Wold & Ison 2013).  
 
The transition to the late phase is marked by the onset of viral DNA replication, a stage 
mediated by the direct participation of E2 encoded proteins (Giberson et al. 2012; Berk 
2013). Consequently, the E2 region transcription reaches its height as the last region of 
the early phase, amounting to higher levels than any other early region (Berk 2013). The 
virus genome is replicated as single-stranded DNA in the presence of only three 
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replication proteins: terminal protein primer, viral DNA polymerase, and the single-
stranded DNA binding protein. The process is biphasic, the synthesis beginning at or near 
the terminal end of one entire strand, followed by the synthesis of the complete 
complementary strand (Lechner & Kelly 1977). All Ad genomes have a hallmark inverted 
terminal repeat (ITR) ranging from 36 to over 200 bp in size (Davison et al. 2003). The 
ITRs act as origins of DNA replication and allow the circularization of single-stranded 
DNA by base-pairing the terminal sequences (Berk 2013). As opposed to conventional 
DNA replication which occurs from the 5’ to the 3’ end, the second complementary strand 
is synthesized from the 3’ to the 5’ end and not as Okazaki fragments (Lechner & Kelly 
1977).   
 
In the late phase, the major late promotor regulates the one late transcription unit (Giacca 
& Zacchigna 2012; Berk 2013). The late gene products include the viral capsid protein 
components as well as proteins that participate in virion assembly (Berk 2013).  Produced 
in the cytoplasm, the structural proteins are transported into the cell nucleus where, upon 
entry, the virion assembly begins. The construction commences 20 to 24 hours after 
infection, initiating with the encasing of the viral DNA in capsid proteins in an event 
requiring the participation of the packaging signal sequence (Ψ) (Berk 2013; Wold & Ison 
2013). Two to three days later, ca 100,000 viral progenies are released by host cell lysis, 
capable of infecting new cells and repeating the infection cycle.  
 
3.3  Areas of application 
 
Ad infect in vitro and in vivo a variety of dividing and nondividing cells that are primarily 
epithelial cells (Boyer et al. 1959; Wold & Ison 2013). Due to beneficial properties, such 
as the proficiency with which the Ad can seize control of the cell machinery for virion 
production and their extensively studied biology, the virus has become an attractive and 
efficient vector in gene therapy and vaccinations (Shiver et al. 2002; Giacca & Zacchigna 
2012; Wold & Ison 2013).  
 
The different Ad vectors are summarized in Figure 5, utilizing the Ad5 genome as an 
example. The genomes are either classified as replication-defective (II and III) or 
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replication-competent (I) vectors (Wold & Ison 2013). The replication-defective vectors 
are utilized in transgene delivery and vaccines while replication-competent vectors are 
applied to cases where Ad replication in a target cell is required. The genome of a 
replication-defective Ad is often modified by deleting one or several essential genes to 
increase the cloning capacity, generating first-, second-, and third-generation vectors.  
 
The first-generation vectors typically have their E1 and/or E3 regions substituted with 
foreign DNA and while the second-generation have additional deletion in the E2 and E4 
regions (Giacca & Zacchigna 2012). Lastly, the third-generation vectors have undergone 
substitution of their whole viral genome aside from regions needed for in cis viral DNA 
replication and packaging. The removal of E1 in all vectors causes the need for in trans 
provision of the encoded protein by specific cell lines to ensure viral replication 
(Danthinne & Imperiale 2000). In the case of the third-generation vectors, a helper vector 
must be supplied in trans, encoding all the necessary proteins (Giacca & Zacchigna 2012).  
 
 
 
 
 
 
 
 
 
 
Figure 5: Summarizing the genetic modifications for different Ad5 vectors: wild-type (I), 
first- and/or second-generation vector (II), third-generation vector (III), Modified from 
Figure 56.10. Wold and Ison (2013). 
 
The Ad vector is an extensively studied virus with much of its structure and function 
elucidated. Due to being a widely utilized vector in gene therapy and vaccination, the Ad 
has undergone several clinical trials that have indicated it to be very well tolerated (Wold 
& Ison 2013). With the genome being relatively easy to modify and a broad range of host 
cells, the Ad has spread to other fields as an attractive vector for different treatments.   
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4  ONCOLYTIC ADENOVIRUSES  
 
OVs are naturally occurring or genetically modified viruses able to infect, replicate in, 
and lyse neoplastic cells (Kaufman et al. 2015). Viruses utilized in this field include e.g. 
coxsackievirus, adenovirus, herpes simplex virus, and vaccinia virus. First applied to 
oncology in the late 1800s when the concept of the nature of a virus was still largely 
unknown, viruses underwent vigorous research as experimental agents in oncology in the 
1950s and 1960s (Kelly & Russell 2007). In the following two decades, interest in viruses 
as cancer destruction agents dwindled while the field of virology remained an area of vast 
interest that has yielded extensive knowledge, making viruses one of the most thoroughly 
understood organisms.  
 
Unique challenges in drug development long prevented the approval of OVs as a new 
class of anticancer drugs (Kaufman et al. 2015). Suboptimal tumor specificity and 
vulnerability to antiviral host defenses have constituted some of the challenges preventing 
the development of an efficient OV treatment (Kelly & Russell 2007). However, with the 
approval of the first treatment for clinical use in the USA and Europe at the end of 2015, 
an important milestone was reached, constituting what is hopefully the beginning of a 
series of efficient cancer treatments of this kind.   
 
One of the predominantly used viruses in clinical development of OV therapies is the Ad 
(Kaufman et al. 2015). Its adaption is propagated by e.g. the ease with which the viral 
pathogenicity can be attenuated, the transgene encoding capacity, as well as the 
established safety of the virus in clinical use. However, to enable extensive clinical 
application of Ad-based therapies it requires the consideration of certain concerns 
regarding the virus. These include the widespread distribution of CAR, strong 
immunogenicity, and the implied need for numerous modifications to both enhance 
oncolytic activity and improve clinical safety (Yamamoto et al. 2017). Some of these 
aforementioned challenges have been exploited to improve Ad-based treatments, such as 
viral immunogenicity. Other issues have attempted to be resolved with the application of 
genome modifications, the details of a few of them being explored in further detail in this 
chapter.  
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4.1  Targeted replication 
 
As opposed to viruses such as the parvovirus and Newcastle disease virus, the Ad 
possesses no natural preference for cancer cells as hosts (Russell et al. 2012). Therefore, 
the Ad must be engineered or adapted for increased cancer specificity by surface or 
genome modification. Structural modifications to the surface of the Ad utilize the fact 
that different serotypes have different tropisms. The Ad applied most extensively in the 
development of OAd belong to the C species, particularly the Ad5, but other emerging 
serotypes with the potential to be OVs in terms of efficacy and safety are, e.g. the Ad 
serotypes 6 and 11 (Shashkova et al. 2009). 
 
There are varying approaches to increase tumor cell infection of the OAd, one focusing 
on the infection pathway. The primary receptor for Ad5 infection of host cells, the CAR, 
is sparingly expressed on many tumor cells because of reduced expression following 
tumor progression (Wold & Ison 2013; Yamamoto et al. 2017). This issue can be 
circumvented with the design of an Ad5 based vector with an RGD motif incorporated 
into the Ad5 fiber knobs (Yamamoto & Curiel 2010; Wold & Ison 2013). This 
modification enables the virus to infect cells through integrin pathways that are abundant 
on cancer cells. Another approach to CAR deficiency is fiber switching, a process 
whereby the part of the Ad5 capsid (the fiber domain) is exchanged for that of another 
serotype (Yamamoto et al. 2017). For one such chimeric vector, the Ad5/3, which is the 
Ad5 virus with the fiber domains of the Ad3, this modification improved tumor cell 
delivery due to CAR-independent infection (Yamamoto & Curiel 2010; Pesonen et al. 
2012).   
 
Another aspect in the selective replication of OAds in cancer cells involves directed 
deletions to specific areas of the Ad genome. As explored in the previous chapter (page 
15), the Ad have the ability of inactivating pathways in host cells to enable the completion 
of the infection cycle. The pathways often referred to are the p53 and the Rb which are 
coincidentally common targets for mutational inactivation in tumors. This can be 
exploited by restricting the OAd proliferation to p53 and/or Rb deficient cells through the 
removal of the innate ability of the virus to inactivate these pathways. Unable to prevent 
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the antiviral response in normal cells, non-tumor cells infected by the modified OAd will 
undergo apoptosis before the infection cycle is completed. Viruses engineered in this 
manner are referred to as conditionally replicating Ads (CRAds).  
 
Among the first examples of CRAds are the viruses ONYX-015 and H101. In these 
viruses, restriction of replication to tumor cells is mediated by the loss of late viral RNA 
export (ONYX-015) or p53 inactivation (H101) by deletions in the E1B-55K gene 
(Bischoff et al. 1996; O’Shea et al. 2004; Yamamoto et al. 2017); see Figure 6 I. Another 
common deletion targets the E1A-CR2 region, limiting the virus replication to Rb 
aberrant tumor cells by disrupting the Rb-binding domain, a deletion also referred to as 
the delta24 (Δ24) (Fueyo et al. 2000; Yamamoto et al. 2017); see Figure 6 II.  
 
 
 
 
 
 
 
Figure 6: Replication-competent Ad genomes. E1B-55K deleted vector (I), E1A mutated 
vector (II), and promoter substituted vector where the promotor of E1A is exchanged for 
a cancer-specific promotor (III). Modified from Figure 56.10. by Wold and Ison (2013). 
 
OAd replication can also be restricted to cancer cells with cancer or tissue specific 
promoters for early gene expression (Buijs et al. 2015). There are several OAds that have 
been designed where the expression of early genes and/or transgenes of interest have been 
regulated with this method, e.g. the CN706 (later renamed CV706) where the E1A 
expression is controlled by a prostate specific antigen promotor for application in prostate 
cancer (Rodriguez et al. 1997; DeWeese et al. 2001); see Figure 6 III. Other promotors 
that have been used with OAds are the cytomegalovirus (CMV), human telomerase 
reverse transcriptase (hTERT) (CGTG-401), and E2F1 (CG0070) (Huang et al. 2016). 
There are also hybrid promotors that have different response elements such as hypoxia 
and the presence of specific hormones driving virus replication. The promotors have been 
applied in viruses used as monotherapies as well as in combination with other treatments. 
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4.2  Efficacy 
 
OV based treatment have long struggled to gain sufficient efficacy, but as recent 
successes with e.g. the T-Vec virus prove, it is a hurdle that can be overcome. 
Immunological treatments such as OVs rely in their mode of action on immune system 
activation, particularly a strong antitumor response. The details of OV mediated 
antitumor immunity is still incompletely understood, but seemingly consists of two 
mechanisms of action: selective replication in tumor cells, culminating in cell lysis, and 
an induced systemic antitumor immunity (Kaufman et al. 2015). Several factors affect 
the respective contribution of the mechanisms, for example characteristics of the OV as 
well as interactions between the virus and the immune system. The ability of OVs to lyse 
tumor cells is influenced by the efficiency of cell receptor targeting, virus proliferation, 
and host cell antiviral response elements.  
 
In the immune storm often created upon OV infection, both innate and adaptive antitumor 
immune responses can be stimulated (Melcher et al. 2011). In fact, it has proven that these 
immune responses triggered by the virus infection are pivotal for the clinical benefit of 
these type of treatments. However, while the virus contributes to an antitumor immune 
response by enabled tumor antigen presentation during an active viral infection, 
neutralizing antiviral measures can impede virus replication and infection of tumor cells 
(Kaufman et al. 2015). How this impacts the therapeutic outcome depends on the 
interplay between these opposing forces. Should the virus cause an antiviral immune 
response, it can induce viral clearance, which in turn impacts the induction of tumor 
immunity. The extent of the influence on tumor immunity may be affected by several 
variables, primarily the characteristics of the virus and the TME.  
 
The immunogenicity of particularly the Ads is an issue that also extends to its 
administration. The capsid proteins of the Ad vector elicit a rapid innate immune response 
upon systemic exposure (Appledorn et al. 2008). This response limits the available time 
for successful infection and systemic spread, which is desired in e.g. metastasize cancers. 
To increase the spreading of the virus to distal tumors, attempts at reducing OV 
immunogenicity have been made (Loskog 2015). Particularly regarding CRAd based 
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therapies, pre-existing immunity is often regarded as a significant hurdle for CRAd 
functionality and has resulted in the immune system being regarded as an impediment to 
OV delivery and efficacy (Yamamoto & Curiel 2010; Melcher et al. 2011). Local 
administration seems to circumvent the issue of neutralizing antibodies on therapeutic 
outcome by resulting in lower levels of antibody formation (Bramson et al. 1997; 
Malmström et al. 2010; Yamamoto & Curiel 2010).  
 
There are several ways to improve treatment efficacy of OVs. Some strategies utilize 
conventional treatments (surgery, radiation therapy, and chemotherapy) in combination 
with OVs. Chemotherapeutic agents that have been used together with OVs include 
cisplatin, docetaxel, and 5-fluorouracil/leucovorin (Russell et al. 2012; Kaufman et al. 
2015). The reasoning behind these combinations rely on the expectation that while the 
OV themselves are unaffected by the concomitant treatments, the virus could target 
residual cancer (Kaufman et al. 2015). Another novel approach is the direct adsorption of 
tumor-specific peptides onto the surface of OAd through electrostatic interactions, 
generating a virus known as PeptiCRAd (Peptide-coated Conditionally Replicating 
Adenovirus) (Capasso et al. 2016). The PeptiCrad utilizes the immunogenicity of the 
OAds to direct the immune response towards the attached exogenous tumor epitopes. This 
approach has shown great promise in animal melanoma models and holds potential for 
further adaptions.  
 
The presence of immunosuppressive cytokines and cells (e.g. tumor growth factor beta 
and regulatory T cells) often impedes the mounting of an antitumor response (Russell et 
al. 2012). In order to target and counteract these tolerogenic functions, the OVs can be 
genetically armed. The armament of the viruses serves to contribute to direct or indirect 
tumor cell destruction or alternatively provide increased focus towards eliciting an 
antitumor response. There is a wide array of genes that can be encoded into the viral 
genomes, ranging from suicide genes to immunostimulatory genes. Immune genes 
successfully incorporated into OAds include granulocyte macrophage colony stimulating 
factor, interferons, tumor necrosis factor-α, interleukin-12, and cytotoxic T-lymphocyte–
associated antigen-4 antibody (Cerullo et al. 2010; Hirvinen et al. 2015; Huang et al. 
2016). 
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However, in regards to the gene encoding capacity, it is worth noting that the Ad has 
evolved an optimized genome and capsid for ultimate aptitude (Kennedy & Parks 2009). 
As such, the substitution of viral genes with therapeutic genes frequently compromises 
this balance by altering the interplay between the genome and the physical structure of 
the virion. Study of the Ad5 has proven that increasing the size of the wild-type viral 
genome over 105% can results in poor vector growth and rapid rearrangement, leading to 
loss of the insert (Bett et al. 1993). Vectors that in turn retain a net genome size below 
105% after DNA insertion are relatively stable and grow well. 
 
In Ad5, an ideal site for transgene insertion is the E3 region because of efficient transgene 
expression (Hawkins et al. 2001). Transgene insertions can disrupt virtually all gene 
coding sequences in the E3, but because the E3 region is comprised of several 
transcription units, over seven E3 proteins can be expressed at varying times and amounts 
during the viral infection. Another area for transgene substitution is in the E1B region 
(Wold & Toth 2013). 
 
4.3 Systemic Immunity 
 
The cancer-immunity cycle is a sequence of steps required for development of effective 
antitumor immunity (Chen & Mellman 2013). These steps involve the activation of the 
adaptive immune system, i.e. the CTLs, an event that has evolved to require specific 
activation signals. These signals involve antigen presentation on MHC-I, the binding of 
a costimulatory molecule, and the secretion of specific cytokines (Thaiss et al. 2011). The 
DCs are catalyzers of the aforementioned signals, enabling them to induce and regulate 
the CTL response towards tumors and viruses. Generally, the DCs are immature and weak 
antigen presenting cells (APC) that possess a high antigen capture activity, low 
costimulatory molecule expression, and restricted cytokine secretion (Veglia & 
Gabrilovich 2017). Following stimulation by pathogens or tissue damage, the activation 
and maturation of the DCs can be initiated which inverts its characteristics to, for 
example, reduce the antigen capture activity and a heightened ability for cytokine 
production.  
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In OV based therapies, following the successful infection and lysis of tumor cells, several 
immunogenic components are released into the TME. These compounds include the 
pathogen-associated molecular patterns (viral particles), danger-associated molecular 
pattern signals (host cell proteins), and tumor-associated antigens (TAAs) (Kaufman et 
al. 2015). The pathogen-associated molecular patterns and danger-associated molecular 
pattern signals elicit an immune response through the activation of specific receptors, e.g. 
Toll-like receptors. In the immunogenic environment that develops, the TAAs are picked 
up, among other antigens, by APCs in the vicinity. The subsequent presentation of the 
antigens on the MHC-I of the amassing DC constitutes the first activation step towards 
DC licensing for cross-priming (Thaiss et al. 2011). Furthermore, the binding of the tumor 
protein partially activates the DCs, prompting them to find a Th1 cell that recognizes the 
captured antigen, now also presented on MHC-II. When found, Th1 cell can provide the 
second activation signal for full DC maturation.  
 
The Th1 cells have costimulatory molecules mounted on their outer membrane, one being 
the CD40 ligand (CD40L). These ligands bind to a corresponding receptor (such as 
CD40) on the surface of the DC which upon stimulation, licenses the DC for CTL 
activation by TAA presentation on the MHC-I (Thaiss et al. 2011). The DC can acquire 
this second signal, e.g. in regional lymph nodes where the priming of naïve CTLs also 
occurs (Thaiss et al. 2011; Turley et al. 2015). This need for a “second opinion” approval 
before CTL activation functions as a safety measure to avoid misguided cytotoxicity 
(Thaiss et al. 2011).  
 
To stimulate CTL expansion and differentiation the T cells require, aside from TAA 
presentation on the MHC-I, the presence of immunomodulatory cytokines which are 
secreted by the licensed DC (Thaiss et al. 2011). The interaction between CD40L and the 
receptor CD40 is known to primarily induce the production of interleukin-12 as the third 
signal for CTL activation (Schulz et al. 2000).  Ultimately, the primed CTLs are guided 
back to the tumor from the blood stream by chemokine gradients and adhesion molecules 
to begin the eradication of cells expressing their cognate antigen (Turley et al. 2015). See 
Figure 7 or the cascade of CTL activation. 
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Figure 7: The activation of the cytotoxic T lymphocytes (CTLs) of the adaptive immune 
system requires three activation signals that are catalyzed by the dendritic cell (DC). The 
activation signals are the binding of an antigen on the major histocompatibility complex 
(MHC) (signal 1), the binding of a costimulatory molecule provided by the T helper 1 
cell (signal 2), and the secretion of specific cytokines and interleukins by the matured DC 
(signal 3). The image was constructed using templates provided by somersault18:24. 
 
The tumor cell death has the potential of causing the release of more tumor antigen which 
upon reaching the draining lymph node can elicit another revolution of the cancer 
immunity-cycle (Turley et al. 2015). Ideally, the cycle culminates in the eradication of 
malignant cells and development of tumor-specific immunological memory, preventing 
tumor progression. It is worth noting that the DC and macrophage mediated production 
of different pro-inflammatory mediators can prove lethal at doses of sufficient magnitude 
(Wold & Ison 2013). In spite of this, CRAd based treatments are regarded as generally 
safe and well tolerated in clinical use when administered locally or at low doses (Pesonen 
et al. 2012; Buijs et al. 2015). 
 
The DCs are essential for antitumor activity, however, simultaneously they are known to 
function inefficiently in cancer (Veglia & Gabrilovich 2017). Stromal cells in the TME 
express molecules, such as interleukins-6 and 10, that can inhibit immune activation by 
suppressing Th cells and CTLs as well as activating immunosuppressive myeloid cells 
(Turley et al. 2015). Numerous approaches have been considered to counteract the 
tolerogenic environment propagated by the tumor cells and TME. 
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4.4. Premise of the Thesis 
 
Immune activation is a key aspect in OV efficacy since it is critical for positive treatment 
outcome. Regarding the adaptive immune system activation cascade, one area of 
improvement is found in acquiring the second activation signal. This stage requires the 
partially activated DC to find the correct Th1 cell while under the tolerogenic pressure of 
the tumor. Furthermore, as stated in an article by Loskog (2015), in the absence of 
cytokine production and sufficient costimulation, the T cells are tolerized rather than 
activated against the antigens presented by the DCs.  
 
The most straightforward solutions to aid in DC maturation is the expression of the 
costimulatory molecule directly in the tumor, utilizing genetic arming of an OAd. This 
approach would enable quick successive acquisition of the two first activation signals by 
the DC, thus shortening the time required to mount an immune response. The transgene 
chosen for the study was one of the most potent costimulatory molecules, the CD40L, 
also known as CD154.  
 
The CD40 ligand is a 33 kilodalton type II transmembrane protein of the tumor necrosis 
factor superfamily, expressed on the surface of both hematopoietic and non-
hematopoietic cells (Aloui et al. 2014). The protein consists of three domains, 
intracellular, transcellular, and extracellular, binding mainly to the 48 kilodalton CD40 
receptor, constitutively expressed on APCs (Henn et al. 2001; Aloui et al. 2014). 
Natively, the CD40L is a membrane bound protein, but a soluble form has been identified. 
The 18 kilodalton soluble CD40L is shed from membrane bound CD40L on activated T 
cells and platelets by protease mediated cleaving of the extracellular domain (Aloui et al. 
2014). Trimeric recombinant soluble CD40L has been found biologically active and able 
to initiate similar functions as the membrane bound form, one being the activation of DCs 
(Mazzei et al. 1995; Mclellan et al. 1999).  
 
Ultimately, the hypothesis of the thesis crystallized into the cascade presented in Figure 
8. Following successful infection of the OAd5, the CD40L would be expressed and 
released alongside TAA upon tumor cell lysis. Binding to the CD40 receptor on partially 
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activated DC, the matured DC could travel to a regional lymph node and prime naïve 
CTLs. Once activated, the CTLs, would expand and return to the infected tumor and 
successfully destroy the remaining tumor cells. Simultaneously, the cytotoxic cells would 
also scourge the body and eradicate any secondary tumors they may come upon, 
effectively curing the patient.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: The hypothesis to acquire improve adaptive immune system activation and 
immunity. Infecting tumor cells with CD40L armed OAd5 (1), viral progenies and the 
transgene are released upon cell lysis (2). The tumor-associated antigen (TAA) and 
CD40L binding (3) enable DC maturation that subsequently allows naïve cytotoxic T 
cells to be primed (4) and return to destroy the remaining tumor cells (5). Additionally, 
tumors encountered elsewhere in the body are also eradicated. The image was made with 
the aid of templates from somersault18:24. 
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5  AIMS  
 
In of the thesis, protocols would be established for the cloning, screening of colonies, and 
primary virus production. Four different transgene variants would be required for the 
subsequent in vitro and in vivo studies. To generate the armed OAd there were three 
distinct aims that needed to be met. 
 
I. Generate four recombined replication-deficient Ad constructs by homologous 
recombination that carry the transgenes encoding for human or mouse variants of 
membrane bound or soluble CD40L.  
 
II. Primary virus and appropriate stock production of all constructs by transfection 
into a virus producing cell line as well as virus propagation and titer 
determination.  
 
III. Elucidation of transgene expression and functionality by immunostaining, 
fluorescence microscopy, Western blotting or ELISA, and Ramos-Blue™ cells 
and QUANTI-Blue™ assay. 
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6  MATERIALS AND METHODS 
 
The following chapter is dedicated to the methods and materials in the generation of the 
Ad5Δ24-CD40L virus. After first recounting the utilized materials, the methods are 
described for the cloning, screening, transfection, and immunostaining in their respective 
sections. Supplementary information is provided in the appendices when necessary.  
 
6.1  Transgenes and Plasmids 
 
The transgenes in the study encoded for the CD40L of human and mouse species. There 
were two forms of the proteins, the native membrane bound form (also referred to as the 
full-length) and the soluble form. The soluble form was designed based on the CD40L 
protein information relayed by the UniProt database, with an additional signal peptide 
incorporated to ensure excretion upon expression. The full-length CD40L amino acid 
sequence was used without further modification, more details on these sequences are 
found in APPENDIX 1. The abbreviations for the different transgenes used from here on 
are relayed in Table 3. 
 
Table 3: The four different constructs design for the study. Human and mouse variants of 
CD40L full-length and soluble transgenes. 
 
 
 
 
 
 
The transgenes were ordered from GeneArt™ with lengths of 786 bp for human full-
length, 783 bp for mouse full-length, and 510 bp for the soluble CD40L of both human 
and mouse origin. In preparation for the cloning, the transgenes were transferred from the 
shipping vector to an in-house shuttle plasmid, the pTHSN, possessing the antibiotic 
resistance gene for ampicillin. The final sizes of the pTHSN carrying the CD40L 
(pTHSN-CD40L) were ca 6,800 bp (full-length) and 6,500 bp (soluble). A plasmid map 
of the empty pTHSN is presented in Figure 9. 
 
Description Human Mouse 
Full-length hCD40L-FL mCD40L-FL 
Soluble hCD40L-S mCD40L-S 
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Figure 9: The shuttle plasmid pTHSN without a transgene, visualizing the location of the 
ampicillin resistance gene (green arrow) and the origin of replication (yellow arrow). The 
plasmid map was made in SnapGene Viewer.  
 
Aside from the pTHSN, the other plasmid used in the study, also found in-house, was the 
rescue plasmid pAd5∆24. Alternatively referred to as the backbone plasmid, it contained 
the whole Ad5 genome aside from a Δ24 deletion, giving it a size of ca 38,800 bp. The 
antibiotic resistance gene in the rescue plasmid was kanamycin. A plasmid map of the 
pAd5∆24 is presented below in Figure 10. The final plasmids would with the full-length 
transgenes be ca 38,600 bp and the soluble transgenes ca 38,400 bp. 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: A depiction of the rescue plasmid pAd5Δ24 with the locations of the 
kanamycin resistance gene (green arrow) and origin of replication (yellow arrow). The 
plasmid map was made in SnapGene Viewer. 
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6.2  Cells  
 
Bacteria and mammalian cells were employed in the study. Three Escherichia coli (E. 
coli) strains were utilized during the cloning process while a mammalian cell line was 
required for the virus production. The competent E. coli JM109, BJ5183, and XL10-Gold 
were all purchased from Agilent Technologies and stored at -80 °C only to be thawed on 
ice briefly preceding transformation. In culture, all E. coli were grown in Luria-Bertani 
medium (LB, Media Kitchen) and incubated at 37 °C and shaking (200-250 rpm) in 14 
ml Falcon® round bottom snap cap tubes (Corning®, cat no: 352059).  
 
The JM109 cells (Agilent Technologies, cat no: 200235) are chemically competent 
recombination proficient E. coli and in this instance utilized solely for the stock 
production and amplification of pAd5∆24 and pTHSN at the very beginning of the study. 
The other recombination proficient E. coli was the BJ5183 cells (Agilent Technologies, 
cat no: 200154) that are electroporation competent cells. The BJ5183 cells were utilized 
in the homologous recombination. The only recombination deficient E. coli strain in the 
study was the XL10-Gold ultracompetent cells (Agilent Technologies, cat no: 200315). 
This strain was utilized for plasmid preservation and amplification for potentially 
recombined plasmids in homologous recombination and Gibson Assembly®. Aside from 
retaining the integrity of transformed plasmids, the XL10-Gold are also well suited for 
large constructs.  
 
The only mammalian cell line in the study was the A549 cells (ATCC). These are 
adherent human lung carcinoma epithelial cells suitable for virus production and 
amplification. The culture conditions for the A549 cells are 37 °C and 5% CO2 in 
complete Dulbeccos Modified Eagle’s Medium (DMEM) 1 g/L glucose (Lonza, cat no: 
BE12-707F/12) supplemented with 10% heat-inactivated fetal bovine serum (Gibco™, 
cat no: 10500064), 1X (2mM) L-glutamine (GlutaMAX™ supplement, Gibco™, cat no: 
35050061), and 1X penicillin-streptomycin (100 U and 0.1 μg/μl respectively) antibiotics 
(Pen Strep, Gibco™, cat no: 15140122). 
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6.3.  Cloning 
 
A large part of the study pertains to the cloning process and the screening for the 
recombined plasmid (pAd5Δ24-CD40L).  The two methods utilized in the cloning were 
homologous recombination and Gibson Assembly®. All generated clones underwent the 
same screening process for the detection of the positive recombined clone. During the 
cloning, other methods such as electrophoresis and spectrophotometry were repeatedly 
employed. 
 
Spectrophotometry is utilized for concentration measurement of DNA after for example 
plasmid isolation and purification or DNA precipitation. For this, the SPECTROstar® 
Nano (BMG LABTECH) was utilized. The DNA concentration could be determined by 
nucleic acid quantitation based on nucleic acids absorption of UV light. The 
concentrations were measured on an LVis Plate with solvent as a blank, which as a rule 
was sterile water (MQ). Spectrophotometry was also used for determining the purity of 
the samples by measuring the ratio between absorbance at the wavelengths 260 nm and 
280 nm, i.e. 260/280 value.  
 
Electrophoresis is the separation and visualization of DNA fragments. The method is 
based upon the negative charge of DNA that generates migration through the mesh of the 
gel from the negative to the positive node when an electric current is applied. The rate 
and ease with which this movement occurs depends on the size and conformation of the 
fragment. Smaller fragments and supercoiled (SC) DNA can move forward with more 
ease whereas larger circular fragments and linearized DNA are retained longer in the 
network of the gel, thereby creating a band pattern. In this study, the electric currents 
ranged between 60 and 100 volts (though generally 70 volts) and were applied for 1-2 
hours, depending on the samples. 
 
Generally, the analysis gels consist of either agarose or polyacrylamide, the latter 
providing a more pronounced separation of fragments close in size. The gels used in this 
project were made from agarose in different concentrations. The tighter gels (1.5% and 
2%) were utilized when separating smaller fragments and the looser gels (0.6% and 0.8%) 
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for larger fragments. The different percentages were attained by dissolving TopVision 
agarose tablets (Thermo Fisher Scientific™, cat no: R2801) in 1X Tris-acetate-EDTA 
(TAE) buffer diluted in MQ (50XTAE, Media Kitchen), which was also used as the 
running buffer during electrophoresis.  
 
For DNA visualization SYBR® Safe DNA Gel Stain (Thermo Fisher Scientific™, cat 
no: S33102) was mixed into the melted agarose and DNA Gel Loading Dye (Thermo 
Fisher Scientific™, cat no: R0611) added to the samples for a final concentration of 1X, 
which facilitated sample loading into the wells of the gel. Two size markers were 
primarily used: λ DNA-Mono Cut Mix (New England Biolab®, cat no: N3019S) for 
bands over 35,000 bp and GeneRuler 1 kb (Thermo Fisher Scientific™, cat no: SM0314) 
for bands under 10,000 bp. The size marker GeneRuler DNA ladder mix (Thermo Fisher 
Scientific™, cat no: SM0331) was used together with BlueJuice™ loading buffer 
(Thermo Fisher Scientific™ cat no: 10816015) for the first two gel runs.   
 
6.3.1  Homologous recombination 
 
Homologous recombination is the traditional way for cloning adenoviral vectors. In this 
method, the transgene is transferred to the desired location in the rescue plasmid with the 
help of homologous regions flanking the transgenes in pTHSN and E3-gp19k in 
pAd5∆24. These homologous regions are identical sequences that can be used to 
essentially switch the transgene into the pAd5∆24 by replicating bacteria. The general 
concept of the method is displayed in Figure 11 below. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: A schematic representation of the homologous recombination using the 
homologous regions. 
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In the first attempt, all four pTHSN-CD40L were used separately in the recombination 
with pAd5∆24. To begin with, all plasmids needed to be linearized prior to 
transformation. The restriction enzyme EcoRI (New England Biolab®, cat no: R0101S) 
was used for pAd5∆24, excising a part of the E3 region from the backbone, and SpeI 
(New England Biolab®, cat no: R0133S) for pTHSN-CD40L. The amount of pTHSN-
CD40L DNA digested of each plasmid was 20 μg in a 50 μl reaction volume with 2 μl 
SpeI. Conversely, 2 μl EcoRI enzyme was added to a 100 μl reaction with 10 μg pAd5Δ24 
DNA. After confirming successful digestion of the plasmids with electrophoresis on a 
0.6% agarose gels (Thermo Fisher Scientific™, cat no: R2801), the 5’ end of pAd5∆24 
was dephosphorylated with calf-intestine phosphatase (CIP, New England Biolab®, cat 
no: M0290S) to minimize the extent of the background due to recircularization. The 
reaction conditions were for all enzymes incubation in a 37 ˚C water bath for generally 
one hour in their respective buffers. 
 
To desalt the cleaved plasmids and remove the enzymes, the DNA was precipitated with 
ethanol. Adding 0.1 volumes of 3 M sodium acetate (pH 5.2, Media Kitchen) to each 
digested plasmid, the mixtures were briefly vortexed before adding 2.5 volumes of -20 
°C 100% ethanol. After another quick vortex, the mixtures were incubated at -20 °C for 
at least an hour. Centrifuging the mixture at 16,000XG and 4 °C for 20 minutes, the 
precipitated DNA became visible as small slightly opaque pellets. Carefully decanting 
the supernatants, the pellets were washed at least once with 1 ml cold 70% ethanol before 
repeating the centrifugation at 16,000XG for 5 minutes. Removing the supernatants, the 
pellets were air-dried ca 10 minutes before dissolution in suitable volumes of MQ. 
 
In the electroporation, the linearized pTHSN-CD40L and pAd5∆24 were transformed to 
BJ5183 cells with a short electric shock to permeabilize the bacterial membrane. As 
recommended by the cell manufacturer, 1 μg pTHSN-CD40L and 0.1 μg pAd5∆24 was 
added to 40 μl bacteria. Transferring the mixtures into chilled Gene 
Pulser®/MicroPulser™ cuvettes with a 0.2 cm gap (Bio-Rad, cat no:1652086), the cells 
were pulsed once in the MicroPulser™ Electroporator (Bio-Rad). The program for E. coli 
cells in a 0.2 cm cuvette was the Ec 2 which delivers a shock of 2.50 kilovolts.  
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After the electroporation, the cells were grown in LB broth without antibiotics at 37 °C 
and shaking to allow their metabolism to commence. An hour later, the bacteria were 
plated in suitable amounts (100 μl, 300 μl, and any remaining volume) onto LB plates 
containing 25 μg/ml kanamycin (Media Kitchen). Following incubation at 37 °C for 48 
hours, ten of the smallest colonies of each construct were plated onto fresh LB-kanamycin 
plates and incubated for another two nights before transferring them to 4 °C for storage. 
 
In the second attempt, only the mouse variants of pTHSN-CD40L were applied (soluble 
and full-length). This time, the pTHSN-mCD40L plasmids were digested with the 
restriction endonucleases SpeI and NdeI (20 μg pTHSN-mCD40L DNA and á 2 μl 
enzyme in one 50 μl reaction). Performing the rest of the protocol as previously described 
for the first attempt, the colonies were grown for 72 hours at 30 °C after which they were 
analyzed directly instead of streaking them onto new plates. Aside from an optimization 
of the screening, the cloning process was otherwise largely the same as described for the 
first attempt. 
 
6.3.2  Gibson Assembly® 
 
In Gibson Assembly®, a polymerase chain reaction (PCR) amplified fragment with the 
human full-length CD40L was transferred into the linearized pAd5∆24 with the use of 
designed overlap regions that should preferably be between 15 to 80 bp long. The two 
DNA strands can be recombined in the presence of select enzymes, which are: 
exonuclease, DNA polymerase, and ligase. These are introduced with the Gibson 
Assembly® Master mix.  
 
The Gibson Assembly® reaction can be divided into three steps according to the functions 
of the different enzymes. First, the exonuclease cleaves the DNA strands from their 5’ 
end, one nucleotide at a time. The subsequently exposed 3’ strand of the backbone and 
the insert anneal with the aid of overlaps. Second, DNA polymerase repairs any remaining 
gaps before, third, the two DNA strands are sealed together with ligase, simultaneously 
removing potential nicks. Applying the reagents and positive control from the Gibson 
Assembly® Cloning Kit (New England Biolabs®, cat no: E5510), the reactions were run 
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at 50 °C for a duration of 15 minutes in a thermal cycler (T100™ Thermal Cycler, Bio-
Rad). The idea behind the Gibson Assembly® and the functions of the different enzymes 
are depicted below in Figure 12. 
 
 
Figure 12: The three main steps in the Gibson Assembly® reaction employing the use of 
exonuclease, DNA polymerase, and ligase to join two DNA strands together. The 
approach enables recombination without the need of bacteria, requiring only incubation 
at 50 °C for at least 15 minutes. 
 
To begin with, an insert with the CD40L transgene was amplified with PCR to incorporate 
the overlaps to insure correct orientation during annealing and ligation of the PCR 
fragment into the backbone. The hCD40L-FL was chosen for the pilot run of this method, 
the primer sets designed to create the different overlaps gathered in Table 4. Per the 
manufacturers instruction, a high-fidelity DNA polymerase was chosen for the insert 
amplification, the Phusion DNA polymerase (Thermo Fisher Scientific™, cat no: F530S). 
As DNA template, 1 ng of pTHSN-hCD40L-FL.  
 
Table 4: The two primer sets used for the PCR amplification of CD40L inserts with 
varying overlaps of 18 to 34 bp. The Tm for the forward primer I is calculated from the 
highlighted area while for the other sequences the Tm is calculated for the whole primer. 
 
Primers Orientation Sequence Tm  Overlap 
Gibson Reaction I 
Primer Set 
Forward 5’- AAT ACT GCG CGC TGA CTC TTA 
AGG ACT AGT TTC GCG CCC TTT C -3’ 
57 °C 24 bp 
Reverse 5’- GTA AAT TTC ATA ATT AAA GAA 
TTC TAA GAA GCT C –3’ 
56 °C 34 bp 
Gibson Reaction II 
Primer Set 
Forward 5’- GCC CAC CGA AAC CGA ATT -3’ 56 °C 18 bp 
Reverse 5’- GTA AAT TTC ATA ATT AAA GAA 
TTC TAA GAA GCT C –3’ 
56 °C 34 bp 
37 
 
There was a total of three Gibson Assembly® reactions in the study. The first two applied 
backbones that were digested using either EcoRI or SpeI and EcoRI-HF (High Fidelity, 
New England Biolab®, cat no: R3101S) restriction endonucleases and corresponding 
inserts. The third approach was intended as a control, the single digested backbone 
combined with an insert designed for the double digested backbone. The double digested 
pAd5∆24 reaction was named Gibson Reaction 1 and the single digested Gibson Reaction 
2.  
 
Because of the previously designed flanking homologous regions, the overlap was 
generated automatically for almost all the primers. However, in the Gibson Reaction I a 
24 bp sequence needed to be added to the 5’ end of the forward primer to generate the 
left-hand overlap. In the initial polymerase reaction, only the 19 bp long highlighted area 
in Table 4 will attach to the pTHSN-hCD40L, integrating this new sequence which will 
thereafter be replicated as part of all the following amplified insert fragments. A detailed 
recounting of the components of the master mix and the PCR cycle are presented in 
APPENDIX 2. The amplification of the CD40L containing fragment was confirmed with 
electrophoresis on a 0.8% agarose gel from which the DNA amount was estimated with 
the GeneRuler 1 kb size marker. 
 
The backbone digestions were done with 10 μg plasmid DNA in a 50 μl reaction with 2 
μl of each enzyme in the double-digestion and 2 μl in the single-digestion. The high 
fidelity EcoRI restriction enzyme was applied in the double digestion to enable the 
addition of both enzymes to the same reaction (100% activity of SpeI and EcoRI-HF in 
CutSmart® buffer). As controls, the backbone was also digested with the SpeI and EcoRI-
HF separately. 
 
Following successful digestion of the pAd5∆24, heat-inactivation of the enzymes, and 
dephosphorylation with CIP, the differently digested backbone DNA were precipitated 
with ethanol as described previously (page 34). Details regarding the backbone 
preparation for the Gibson Assembly® are recounted in APPENDIX 2. The DNA was 
resuspended in MQ and the concentration determined with spectrophotometry. 
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The optimal DNA quantities were calculated according to Equation 1 per the kit 
manufacturer’s instructions. The quantities ultimately used were 0.05 pmol PCR 
fragment, 0.02 pmol of the SpeI and EcoRI-F digested backbone, and 0.03 pmol of the 
EcoRI digested backbone. Less of the double-digested backbone was used to minimize 
the introduction of disturbing elements from the digestion to the assembly reaction. 
Backbone and corresponding PCR fragments were added to 1X Gibson Assembly Master 
mix and MQ for a final volume of 20 μl. Loading the reactions onto eight tube strips from 
a FrameStar® Break-A-Way 96-well PCR plate (4titude) with flat capped removable 
strips, the assembly conditions were 50 °C for 15 minutes before being moved to -20 °C 
to await transformation. Aside from combining the single digested backbone with the 
wrong insert as a negative control, the positive control provided with the Gibson 
Assembly® kit was also utilized.  
 
pmols = (weight in ng) x 1,000 / (base pairs x 650 Daltons) 
 
Equation 1: The formula utilized in calculating the number of pmol for the fragments to 
ensure optimal assembly.  
 
As recommended by the manufacturer, the Gibson Assembly® reaction was diluted 1:4 
prior to transformation to XL10-Gold cells. The transformation to the recombination 
deficient ultracompetent bacteria XL10-Gold was accomplished with heat shock. 
Prechilling all equipment used to handle the bacteria prior to the transformation, the cells 
were thawed on ice and divided into 50 μl aliquots. After incubating the cells with β-
mercaptoethanol to improve the transformation efficiency, 2 μl of the diluted Gibson 
Assembly® reaction was added to an aliquot of bacteria. Following a 30-minute 
incubation period to allow the DNA to attach to the outside of the bacteria, the DNA was 
internalized with a 42 ˚C heat-pulse lasting 30 seconds. Chilling the bacteria on ice for 2 
minutes afterwards, prewarmed 42 ˚C NZY+ broth (Media Kitchen) was added and the 
bacterial solution incubated for an hour under shaking at 37 ˚C. Finally, the bacteria were 
plated on LB-kanamycin plates and incubated overnight at 37 ˚C. 
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6.4  The Screening Process 
 
Whether after homologous recombination or Gibson Assembly®, identifying the 
correctly recombined plasmid was essential and therefore several control points were 
implemented throughout the cloning process. The three main screening methods 
employed served to confirm the presence of various critical elements of the final 
recombined plasmid, providing increasing confidence in that the final construct was the 
correct one, without the need for sequencing. First was the positive selection of 
transformed bacteria that carried either the backbone or recombined plasmid through 
antibiotic selection, second colony PCR to isolate the bacteria with the transgene, 
followed by the third and final control point, restriction analysis, to establish the presence 
of the transgene in the backbone as well as the retained integrity of vital areas of the 
construct.  
 
The antibiotic selection during cloning is a standard procedure and was a process that 
underwent no modification during the presented study, the antibiotic resistance gene and 
placement being predetermined. The colony PCR was a protocol implemented and 
improved throughout the different cloning attempts and will be presented along with the 
restriction analysis in greater detail in the section below. 
 
6.4.1  Colony Polymerase Chain Reaction  
 
Colony PCR is a robust high capacity screening method employing the speed of PCR and 
the selectivity of the primers in the analysis of a large quantity of bacterial colonies for 
the desired insert. The process involves picking a single bacterial colony, adding it to the 
PCR reaction to provide a template, and then preserving the colony by inoculating it in 5 
ml of LB with antibiotics. Inoculation allows for further expansion of the bacteria that 
give a positive signal, implicating them as possible carriers of the recombined plasmid; 
Figure 13 visualizes the colony PCR process. 
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Figure 13: The steps in colony PCR from how the colony is analyzed to how the bacteria 
is preserved. Transformed bacteria are grown under antibiotic selection on an LB plate, 
after which the colonies are picked for colony PCR and the plasmid preserved by 
inoculation into 5 ml LB with antibiotics. 
 
Forward and reverse primers were designed that bound to ca 20 bp long sequences 
flanking the transgenes. The location of the recognition sequences for the primers in 
relation to the transgenes enable the use of the same primers for all four intended 
constructs. Four primer sets were vetted, out of which two were chosen for the colony 
PCR (Table 5). As the protocol was optimized in the second homologous recombination 
attempt, only one primer set was ultimately used, consisting of the forward primer from 
Primer Set I and the reverse primer from Primer Set II. Furthermore, while initially the 
high-fidelity DNA polymerase Phusion was utilized in the screening, it was later replaced 
by DreamTaq DNA polymerase (Thermo Fisher Scientific™, cat no: EP0702). The latter 
polymerase lacks proof-reading abilities, but provided sufficient accuracy at a lower cost 
for this application.  
 
Table 5: The primer sets used in colony PCR, first separate and later by combining the 
forward primer of Primer Set I and the reverse primer of Primer Set II. 
Primers Orientation Sequence 
Tm °C 
Phusion 
Tm °C 
DreamTaq 
Primer Set I 
Forward 5’– ACG CGG AGG CTC TCT TCA GTA –3’ 67.7  62.1 
Reverse 5’– CCG GAC GGA GAC CAA GCG –3’ 71.9  63.8 
Primer Set II 
Forward 5’– CCC AGA CGG AGT GAG TCT AC –3’ 61.9  58.5 
Reverse 5’– CCT GAC TTC AAG GTT GTA GCG–3’ 64.1  57.3 
41 
 
Different approaches were tested for the addition of the bacterial template. Generally, the 
colony is analyzed by touching a pipette tip to it and then dipping the tip in the PCR 
master mix. The approach that proved most effective in this study was the inoculation of 
colonies in 5 ml of LB with 25 μg/ml kanamycin (Media Kitchen) and growing them 
under shaking overnight at 37 °C. In the morning, 30 μl of the inoculate was diluted in 70 
μl MQ and then boiled for 10 minutes at 98 °C to ensure release of the plasmid.  Finally, 
20 μl of mixture was added to the prepared PCR reaction. The dilution was essential, both 
to reduce the inhibitory effect of the LB, as well as to reduce the amount of template 
added to the reaction. The amount of MQ was reduced from the final volume added to 
the master mix for a correct final concentration of the components.  
 
All PCR reactions were pipetted on ice and the preparations for the PCR reactions were 
performed at a different site to the subsequent analysis of the PCR amplified products to 
avoid DNA cross-contamination. The reactions occurred on eight tube PRC strips with 
positive (pAd5∆24 SC) and negative controls (MQ). A detailed description of the reagent 
concentrations in the master mix as well as the PCR cycle are found in APPENDIX 3. 
The colony PCR reactions were analyzed on a 2% agarose gel to determine the possible 
presence and size of PCR amplified product. The bacteria in the 5 ml inoculums for the 
colonies that gave positive signals were collected in 2 ml microcentrifuge tubes. The 
plasmid DNA was extracted with QIAGEN® Plasmid Minikit (ref no: 12123) following 
the instructions provided with the kit (APPENDIX 4). The formed plasmid DNA pellet 
was resuspended in MQ and transferred to -20 °C for storage until further analysis. 
 
6.4.2  Restriction Analysis 
 
Restriction analysis was employed to assess the presence of all desired elements in the 
recombined plasmid which would be needed for the subsequent virus production. In 
restriction analysis, it is presupposed that a plasmid has a definite number of restriction 
enzyme sites. When cleaved with their respective enzymes, the result will be a certain 
number of bands of a certain size that can then be separated on an analysis gel to give a 
band pattern. The band pattern can in turn be utilized in judging the presence of certain 
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components in the plasmid. In this study, the elements of special interest were the 
successful integration of the transgene and the retained integrity of the area by the ITRs. 
 
Three different restriction enzymes were utilized in the study: PacI (New England 
Biolab®, cat no: R0547S), HindIII (High Fidelity, New England Biolab®, cat no: 
R3104S), and BamHI (High Fidelity, New England Biolab®, cat no: R3136S). The PacI 
digestion ascertained the integrity of the area by the ITRs which is crucial for the primary 
virus production. The BamHI and HindIII were, in turn, utilized in the detection of the 
transgene in the backbone, the BamHI for the mouse variants and the HindIII for the 
human variants. The expected restriction sites in the final recombined plasmid for all three 
restriction enzymes are displayed in Figure 14. A detailed account for reagent amount in 
each restriction digestion is gathered in APPENDIX 5. 
 
 
Figure 14: The restriction enzyme sites for (from left to right) PacI, HindIII, and BamHI 
in the recombined pAd5Δ24-CD40L. 
 
All digestion reactions were prepared on ice and subsequently incubated at 37 °C for 1-2 
hours before being moved onto ice. Cleaved plasmid DNA was added to the wells and 
separated according to size with electrophoresis on 0.8% agarose gels. The generated 
band patterns were compared to an expected pattern predicted based on the plasmid maps. 
The empty pAd5∆24 was used as a control in all restriction reactions.  
 
6.5  Transfection 
 
In preparation for the transfection of the recombined plasmids to the A549 cells, sufficient 
plasmid DNA was needed. Therefore, the Gibson Assembly® generated plasmids and 
empty pAd5∆24 were transformed to XL10-Gold cells with heat shock for plasmid 
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amplification. Following the transformation protocol provided by the manufacturer, the 
bacteria were afterwards grown under 25 μg/ml kanamycin selection on LB plates. 
Inoculating single bacterial colonies in 5 ml LB and 25 μg/ml kanamycin, the bacterial 
solutions were ultimately increased to 135 ml preparations. After growing the bacteria to 
an optical density at 600 nm of ca 4, the bacterial solutions were transferred for long-term 
storage in 1 ml 15% glycerol (99.5% glycerol stock, Media Kitchen) preparations.  
 
The remaining bacteria were then harvested and the plasmids purified with the 
Nucleobond XtraMidi kit (Macherey-Nagel, cat no: 740410.50); a detailed account of the 
manufacturers protocol is provided in APPENDIX 6. Afterwards, all plasmids were 
cleaved using PacI restriction endonuclease in two separate reactions, each containing 5 
μg DNA, followed by electrophoresis. After confirmed digestion, the two restriction 
reactions were purified. The A549 cells were taken into culture, grown in complete 
DMEM and split in the ratio 1:4 two to three times a week at around 80-90% confluency 
in T75 ventilated cap flask (Sarstedt order no: 83.3911.002). The transfection was first 
attempted with the ViraPack Transfection Kit (Agilent Technologies, cat no: 200488), 
followed by the QIAGEN® Effectene Transfection Reagent (QIAGEN®, cat no: 
301425). 
 
Prior to the ViraPack transfection, the duplicate DNA samples were pooled by running 
them through the QIAGEN-tip 20 from the QIAGEN® Plasmid Minikit. The recovery of 
DNA was tested prior with 20 μg pAd5Δ24 DNA which according to the user manual 
was the maximum preparation capacity of high-copy plasmid or cosmid DNA. For the 
DNA purification, the tips were equilibrated with 1 ml Buffer QBT, after which the DNA 
was applied dropwise in 50 μl aliquots. Washing the columns twice with 2 ml Buffer QC, 
the DNA was eluted with 65 ˚C warm 0.8 ml Buffer QF. Finally, the DNA was 
precipitated with 0.56 ml room temperature isopropanol by centrifugation at 4 ˚C at 
16,000XG for 30 minutes.  Washing the DNA with room temperature 70% ethanol, the 
DNA was precipitated anew before air drying and resuspension in 25 μl MQ. The 
purification method above was not repeated for the QIAGEN® Effectene transfection, 
where the DNA was simply precipitated with ethanol (see section 6.5.1 on page 44 for 
more details). 
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6.5.1  ViraPack Transfection 
 
The ViraPack transfection kit user manual details that the kit utilizes the calcium 
orthophosphates method that enables transfection by increasing cell membrane 
adsorption and subsequent uptake of DNA by the cells. To begin with, A549 cells were 
grown to 80% confluency before trypzinizing them with 1X TrypLE™ Express Enzyme 
(Gibco™, cat no: 12604013) for 10 minutes. Gently tapping the sides of the bottle to 
ensure all the cells are dislodged, the enzyme is inactivated with addition of fresh 
complete DMEM media. Washing the cells slowly along the bottom of the flask, potential 
clusters of cells are resuspended before transferring a portion of the cells to a new T75 
flask for continuation.  
 
A 5-ml portion of the cell suspension was diluted 1:1 in fresh media and briefly vortexed 
to assure homogenous suspension of the cells. Mixing 10 μl of the dilution with an equal 
volume trypan blue, 10 μl was pipetted into a Countess® cell counting chamber slide 
(Thermo Fisher Scientific™, cat no: C10228). Details from the cell counting is gathered 
in APPENDIX 7. The transfection was done in T25 ventilated cap flasks (Greiner, cat no: 
690175) at a cell density of 250,000 cells/flask, which amounted to 144 μl of the cell 
suspension to 5 ml complete media. The cells were then incubated overnight.  
 
On the day of infection, around 1 μg DNA of two recombined Gibson plasmids, 
pAd5∆24, pAd5/3∆24, and a green fluorescent protein (GFP) plasmid were prepared for 
transfection in sterile BD Falcon® 5 ml polystyrene round bottom tubes (BD Biosciences, 
cat no: 352235) according to the ViraPack Transfection Kit instructions. The empty 
pAd5∆24 and pAd5/3Δ24 (in-house) were controls for the virus production while the 
GFP plasmid functioned as a positive control for the transfection.  
 
During the transfection, DMEM containing 1X glutamine and 6% modified bovine serum 
solution was used according to the manufacturers recommendations. After adding the 
DNA to the cells, the transfections were incubated for three hours at 37 °C and 5% CO2. 
Removing the media, the cells were washed with 1X phosphate-buffered saline (PBS, 
Media Kitchen) thrice before ensuring the complete removal of DNA complex 
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precipitate. Exchanging the PBS with 5 ml complete DMEM the cells were incubated at 
37 ˚C and 5% CO2. The transfections were observed during a week for cytopathic effect 
(CPE), replenishing the growth medium as needed according to its color. The GFP 
transfected cells were monitored for fluorescence to determine the success of the DNA 
transfection. A detailed account of the protocol provided by the manufacturer can be 
found in APPENDIX 8. 
 
6.5.2  QIAGEN® Effectene Transfection   
 
The Effectene Transfection Reagent is described by QIAGEN® as a nonliposomal lipid 
formula that together with the DNA enhancer and DNA-condensation buffer offer a high 
transfection efficiency. The transfection is achieved by the Effectene reagent coating the 
enhancer condensed DNA molecules with cationic lipids, enabling the complex to 
transfer into the cell. The possibility of carrying out the transfection in the presence of 
serum provide low cytotoxicity, making the transfection highly suited for sensitive cell 
lines or primary cells. Furthermore, for most cell types there is no need to remove the 
transfection-complex.  
 
To begin with, the A549 cells were cultured to around 80% confluency at which point 
they were trypsinized and counted in the same manner as described on page 44; details of 
the cell count are found in APPENDIX 7. With a desired cell density of 800,000 cells per 
T25 ventilated cap flasks (Sarstedt, order no: 83.3910.002), a volume of 364 μl was added 
per 5 ml complete DMEM. While incubating the flasks for 2 hours, DNA dilutions were 
prepared for the transfection with the QIAGEN® Effectene Transfection Reagent. 
Following the instructions provided by the manufacturer (see APPENDIX 9), the 
transfection was performed with the same plasmids as in the ViraPack transfection. 
Around 1 μg DNA was used for all constructs, except the second recombined plasmid 
where only 0.25 μg DNA was added. The cells were incubated in complete media at 37 
˚C and 5% CO2 and monitored in the manner described for the ViraPack transfection for 
signs of GFP and CPE.  
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After QIAGEN® Effectene Transfection, the transfected A549 cells were harvested upon 
detection of sufficient CPE. Gently tapping the sides of the dishes to dislodge any attached 
cells, the cell suspension was transferred to 15 ml centrifuge tubes (Sarstedt, order no: 
62.554.502). Separating the cells from the media by centrifugation at 500XG for 10 
minutes at 4 °C, all but 2 ml of the supernatant was removed. Resuspending the cells by 
vortex, the cell suspensions were subjected to four freeze-thaw cycles to free the primary 
virus from within the cells. The freeze-thaw cycle consisted of freezing at -80 °C and 
rapid thawing in a 37 °C water bath. The centrifugation of the suspension was repeated 
at 500XG and 4 °C for 10 minutes after the fourth round. To amplify the primary viruses, 
the supernatants or viral lysates (á 2 ml for each virus) were pipetted to separate T75 
flasks with A549 cells in complete DMEM at around 80-90% confluency and incubated 
between three to six days, depending on the development of CPE. Next, the presence of 
the virus and the expression of CD40L was confirmed with immunostaining.  
 
6.6 Immunostaining 
 
Following a round of virus amplification, the produced viruses were analyzed with 
immunostaining, using antibodies for the hexon and CD40L proteins. For this, A549 cells 
were seeded into the wells on a 12-well plate (Sarstedt, order no: 83.3921) at a cell density 
of 100,000 cells per well. Afterwards, the cells were allowed to adhere and divide for a 
final confluency of 50-60% on plastic cover slips (Ø 13 mm, no 1.5, VWR®, cat no: 631-
0150). Performing the staining twice, in the first staining the cells were fixed with 
paraformaldehyde or methanol, providing the need for duplicate 12-well plates. In the 
second staining, only methanol fixed cells were used. 
 
The recombined viruses (both Ad5∆24-hCD40L), the Ad5∆24, and two other in-house 
viruses (Ad5/3-hCD40L-CMV and Ad5/3-CD40L-h-TERT) were stained. The viruses 
were diluted 1:100 in complete DMEM and added 48 hours after seeding the A549 cells 
onto the coverslips. The layout of the 12-well plate is presented in Figure 15 on page 47. 
In the wells used as negative controls (-), the media was simply changed. In the first 
staining, the viruses were left to infect the cells for a period of 24 hours and extended to 
48 hours for the second staining of methanol fixed cells.  
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Figure 15: The mapping of the different samples for immunostaining on the 12-well plate. 
All samples were made in duplicates and included both constructed viruses Gibson 
Plasmid virus 1 (GP 1) and Gibson Plasmid virus 2.1 (GP 2.1). The positive controls were 
the Ad5/3-hCD40L-CMV (CMV), Ad5/3-CD40L-h-TERT (TERT), and Ad5∆24 and 
mock (-). 
 
In the paraformaldehyde fixation, the old media was removed and the cells washed twice 
with 1XPBS. Adding 3.5% paraformaldehyde in PBS to the cells, the cells were left for 
20 minutes at room temperature, followed by three washes with 1XPBS. For blocking the 
cells, 3% bovine serum albumin (Media Kitchen) in 1XPBS was added to each well and 
left for 10 minutes. Diluting the primary antibodies for the CD40L (ab 231 rabbit-anti-
CD40L) and the hexon protein (8C4 mouse-anti-adenovirus), both were added 
simultaneously and incubated for 1 hour. Washing the coverslips twice with 1XPBS, the 
secondary antibodies were added, goat anti-rabbit Alexa 488 for the CD40L and goat anti-
mouse Alexa 594 for the hexon protein, and incubated in the dark for another hour. 
Washing the cells thrice with 1XPBS, the Hoechst reagent (in-house) was diluted 1:10 
000 and after addition left for ca 1 minute. Washing the coverslips one last time in 1XPBS 
and MQ, they were mounted and imaged with EVOS FL Cell Imaging System. 
 
Cells were fixed with methanol 24 hours and 48 hours after virus addition, at which point 
the old media was aspirated and the cells washed once with 1XPBS. Adding around 1 ml 
of -20 °C 100% methanol to each well, the plates were incubated in the freezer for ca 11 
minutes. Removing the methanol, the cells were washed thrice with 1XPBS. The staining 
was done as previously described, with the exception that the 48-hours infected cells were 
incubated primary and secondary antibodies in the dark. After mounting, the cells were 
imaged with EVOS FL Cell Imaging System. 
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7  RESULTS 
 
The results from the cloning, transfection, and immunostaining are recounted in the 
subsequent chapter. The results from the homologous recombination and Gibson 
Assembly® are presented chronologically with supplementary information provided in 
the appendices.  
 
7.1  First Homologous Recombination 
 
The homologous recombination was attempted in two rounds. In the first attempt, the 
shuttle plasmids with the four different transgenes were linearized with the restriction 
enzyme SpeI. The digestion was confirmed with electrophoresis, visualizing the cleaved 
pTHSN-CD40L plasmids as ca 6,600 bp bands; the ca 200 bp size difference between the 
plasmids generated by the varying lengths of the soluble and membrane bound transgenes 
are indiscernible on the 0.6% agarose gel presented in Figure 16.  
 
 
Figure 16: The four SpeI digested pTHSN-CD40L of all four origins with two of the 
undigested pTHSN-CD40L as controls for the first homologous recombination. The 
amount of DNA loaded onto the gel amounts to 1 μg each. 
 
The backbone plasmid was prepared by digestion with the dual cutter EcoRI, excising a 
ca 2,700 bp band where the plasmid would be inserted. The bands were separated on a 
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0.6% agarose gel following a one-hour incubation at 37 ˚ C (Figure 17). The DNA amount 
loaded onto the gel was 0.5 μg (lane 3 and 5) and 1 μg (lane 2 and 4); the SC pAd5Δ24 
was used as control.  
 
 
Figure 17: Determination of the successful cleavage of the pAd5Δ24, with the uncut 
backbones as controls. Two different DNA amounts were loaded of both plasmids, 0.5 
μg (3 and 5) and 1 μg (lane 2 and 4). 
 
After simultaneous transformation of á 1 μg pTHSN-CD40L of one of the four transgenes 
and 0.1 μg pAd5∆24 to BJ5183 cells, the bacteria growing under kanamycin selection 
were screened with colony PCR. Ten colonies of each transgene were analyzed with two 
separate primer sets that had previously been verified for their functionality. The results 
for the testing of the four primer sets are gathered in APPENDIX 10. The screened 
colonies were visualized for potential PCR amplification product on 2% agarose gels. 
First, ten clones from the pTHSN-hCD40L-FL and pAd5Δ24 transformation were 
screened. The results from Primer Set I are presented in Figure 18 and Primer Set II, with 
the same colonies in the same order, in Figure 19. 
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Figure 18: The gel run on a 2% agarose gel from the colony PCR of the ten hCD40L-FL 
transformed bacterial colonies. Here Primer Set I was used and four signals were 
observed. 
 
 
Figure 19: The results from the colony PCR with Primer Set II and ten hCD40L-FL 
transformed bacterial colonies, run on a 2% agarose gel. Seven signals were observed. 
 
Ten bacterial colonies with the transformed hCD40L-S transgene were screened next. 
The colonies amplified with Primer Set I are in Figure 20 and those with Primer Set II in 
Figure 21. The corresponding mouse constructs (full-length and soluble) are found in 
APPENDIX 11.  
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Figure 20: Colony PCR amplified product for ten hCD40L-S transformed colonies using 
Primer Set I. Six clear signals were observed on the 2% agarose gel.  
 
 
Figure 21: The amplified colony PCR products using the Primer Set II for ten hCD40L-
S transformed colonies. Seven signals were observed on the 2% agarose gel. 
 
A total of 40 bacterial colonies were screened in the first homologous recombination 
attempt, out of them, 18 were deemed positive. The two colonies with the strongest 
signals that emerged for both primer sets of each construct was initially chosen for 
continued analysis with restriction enzymes. The colonies in Table 6 were the first that 
underwent plasmid extraction and restriction analysis. 
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Table 6: Two colonies of each constructs, providing a PCR product with both Primer Set 
I and Primer Set II that were chosen for further analysis.  
 
 
 
 
 
 
In restriction analysis, the expected band pattern from the digestion of PacI, HindIII, and 
BamHI are relayed in Table 7. Depending on whether the construct contains the soluble 
or full-length variant of the transgene, there may be small variations in the size of the 
bands; these differences would, however, often be indiscernible on an agarose gel. The 
results from the restriction analysis with PacI are presented in the Figure 22 and the results 
using HindIII and BamHI in Figure 23. All three digestion products were analyzed on 
0.8% agarose gels. In the HindIII digestion, the ca 5,700 bp band in the empty pAd5Δ24 
is cleaved into two bands, ca 2,600 bp and 3,100 bp in size,  because of the introduction 
of an additional HindIII recognition sequence with the transgene. 
 
Table 7: The calculated sizes based on the plasmid maps  in SnapGene Viewer for the 
different fragments produced during restriction analaysis with PacI, HindIII, and BamHI 
of the recombined plasmids and the empty pAd5Δ24. The sizes are recounted as kilo 
base-pairs (kb).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Construct Colony  
hCD40L-FL 1 and 4 
hCD40L-S 2 and 4 
mCD40L-FL 1 and 2 
mCD40L-S 2 and 8 
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Figure 22: The band pattern for the potential positive clones selected with colony PCR 
on a 0.8% agarose gel. The PacI digestion is expected to yield two bands, one ca 2,900 
bp and the other ca 35,000 bp for mouse constructs and ca 36,000 bp for human constructs 
and the control, pAd5Δ24. 
 
Figure 23: The results from the HindIII and BamHI of the suspected positive clones of all 
four constructs on a 0.8% agarose gel. For the BamHI digested constructs carrying the 
mouse transgenes, a band would be cleaved, the same for the HindIII digested plasmids 
carrying the human transgenes. 
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Upon separation of the products from the restriction analyses with PacI, BamHI, and 
HindIII, the background was substantial with the appearance of superfluous bands at 
varying intensity. Most notably, none of the PacI digestions presented the successful 
excision of a 2,900 bp band. This implied loss of structural integrity precluded the 
generation of operational viruses, requiring the cloning to be attempted anew.  
 
7.2  Second Homologous Recombination 
 
In the second attempt, only the mouse CD40L constructs were used, being double 
digested with SpeI and NdeI. The digestions were, as previously, confirmed on a 0.8% 
agarose gel (Figure 24) before proceeding with cotransformtion to BJ5183 cells; digested 
backbone from the first attempt at homologous recombination was utilized. The double-
digested plasmids should yield bands approximately 4,300 bp and 3,000 bp in size for 
pTHSN-mCD40L-FL and 4,000 bp and 3,000 bp for the pTHSN-mCD40L-S. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: The NdeI and SpeI double digested pTHSN-mCD40L-FL and pTHSN-
mCD40L-S on a 0.8% agarose gel. The controls were the same undigested constructs.  
 
With the optimized combined primer set in the second attempt, a PCR fragment would 
be produce for both the empty pAd5Δ24 and all pAd5Δ24-CD40L. The different 
constructs would yield different sized PCR products: pAd5∆24 a ca 2,400 bp band, 
pAd5∆24-CD40L-FL a ca 2,200 bp band, and pAd5Δ24-CD40L-S a ca 1,900 bp band. 
Out of the 25 screened pAd5Δ24-mCD40L-FL clones, three were positive (Figure 25 
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lanes 3 and 5, Figure 26 lane 2) and out of the 45 screened pAd5Δ24- mCD40L-S 
colonies, one was positive (Figure 26 lane 8). The other samples screened yielded no PCR 
product and were empty as, for example, lane 6 through 12 in Figure 25. The colony PCR 
gel run of these samples are not included.  
 
Figure 25: The gel run of the pAd5Δ24-mCD40L-FL colony PCR. The samples were run 
on a 1.5% agarose and two were potential positives. 
 
 
Figure 26: The results from the colony PCR of bacteria transformed with full-length and 
soluble mCD40L after electrophoresis on a 1.5% agarose gel. One mCD40L-FL and one 
mCD40L-S were deemed potential positive clones. 
 
Isolating the plasmids from the potential positive clones (three pAd5Δ24-mCD40L-FL 
and one pAd5Δ24-mCD40L-S) they were transformed to XL10-Gold cells for plasmid 
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preservation and propagation. After isolating the plasmids from 135 ml preparations, 
exceptionally 6 μg DNA was digested with PacI or BamHI for restriction analysis to 
ensure visibility. The digestion products were separated on 0.8% agarose gels (Figures 
27 and Figure 28).   
 
 
 
 
Figure 27: The PacI digested potential positive clones carrying mCD40L-FL run on a 
0.8% agarose gel. The expected band pattern for positive clones is two bands, 
approximately 2,900 bp and 36,000 bp in size. 
 
 
 
 
Figure 28: The BamHI digested potential positive clones run on a 0.8% agarose gel to 
confirm the presence of the mCD40L-FL transgene. Successfully recombined constructs 
will present as three bands, ca 7,000 bp, 7,300 bp, and 24,000 bp in size. 
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The resolution of the products from the restriction analyses was significantly improved 
compared to the first attempt (Figures 22 and 23 on page 53). Still, the issue of the PacI 
digestion persisted in proving the current protocols failure to retain the structural integrity 
to vital areas of the assembled product. In the subsequent attempt, a novel in vitro 
recombination method was exchanged for the traditional homologous recombination. 
 
7.3  Gibson Assembly® 
 
In Gibson Assembly®, the backbones were digested with either SpeI and EcoRI-HF 
restriction endonucleases or EcoRI alone. The digestions were confirmed on 0.8% 
agarose gels (Figure 29 and 30).  For the transgene inserts, the amplification was done for 
both soluble and full-length hCD40L, using 1 ng and 10 ng of pTHSN-hCD40L as 
template. The reaction with 1 ng pTHSN-hCD40L-FL DNA initially added was 
ultimately applied to the assembly reaction. The verification of insert production is seen 
in Figure 31. Primer set I (for SpeI and EcoRI-HF digested) yielded bands ca 2,800 bp 
for the hCD40L-FL or ca 2,500 bp for the hCD40L-S. Primer Set II (EcoRI digested) 
generated bands either ca 2,600 bp bands for the hCD40L-FL and 2,300 bp bands for the 
hCD40L-S. 
 
 
Figure 29: The single and double digested pAd5Δ24 using SpeI and/or EcoRI-HF in 
preparation for Gibson Assembly® on a 0.8% agarose gel. The SpeI digested vector is 
linearized into a ca 38,800 bp band while the SpeI and EcoRI-HF restriction analyzed 
vectors present as primarily two bands, ca 35,900 bp and 2,700 bp in size. 
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Figure 30: The gel run of the EcoRI digested pAd5Δ24 for Gibson Assembly®. The 
samples were run on a 0.8% gel. Bands ca 2,700 bp and ca 35,900 bp confirmed 
successful digestion. 
 
Figure 31: Production of the transgene insert for Gibson Assembly® using 1 and 10 ng 
of either pTHSN-hCD40L-FL or pTHSN-hCD40L-S as template separated on a 0.8% 
agarose gel. Primer set I (PSI) yielded bands ca 2,800 bp (hCD40L-FL) or ca 2,500 bp 
(hCD40L-S), and primer Set II (PSII) ca 2,600 bp bands (hCD40L-FL) and 2,300 bp 
bands (hCD40L-S). 
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After the transformation of the diluted Gibson Assembly® reaction product, 78 colonies 
were analyzed with colony PCR out of which three positives were found (see lanes 2, 7, 
and 10 in Figure 32). According to estimations made from the plasmid maps, the PCR 
should generate a band ca 2,200 bp for pAd5Δ24-hCD40L-FL and a band ca 2,400 bp for 
the pAd5Δ24 with these primers. The remaining 75 screened colonies gave no signal. The 
plasmids were named Gibson plasmid 1, Gibson plasmid 2.1, Gibson Plasmid 2.2. The 
Gibson Plasmid 1 was made with the SpeI and EcoRI-HF digested backbone and 
corresponding insert while the Gibson Plasmid 2 were made with the EcoRI digested 
backbone and corresponding insert.  
 
Figure 32: Results from the colony PCR with three potential positive clones produced  
with Gibson Assembly®.  
 
The restriction analysis with HindIII and PacI fragments were separated on 0.8% gels as 
seen in Figure 33 on the following page; the controls were for both enzyme reactions the 
empty pAd5Δ24. The HindIII digestion were run on lanes 2 through 6, and the PacI 
digestion run on lanes 8 through 11. All desired bands were seen with both enzymes for 
all constructs, albeit with less DNA for of the Gibson Plasmid 2.2. For further 
confirmation of successful transgene insertion, the PCR amplified products from the 
colony PCR for Gibson Plasmid 1, Gibson Plasmid 2.1, and Gibson Plasmid 2.2 were 
also digested with HindIII. Separating these fragments on 2% agarose gels, the successful 
cleaving was confirmed (Figure 34). Based on the restriction analyses, Gibson Plasmid 1 
and Gibson Plasmid 2.1 were ultimately chosen for transfection. 
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Figure 33: Restriction analysis for the Gibson Plasmids with HindIII and PacI restriction 
enzymes. The presence of the transgene can be judge by an emerging band above the 
green line, ca 2,600 bp in size, in the HindIII digestion. PacI digestions should yield bands 
approximately 2,900 bp and 36,000 bp large.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34: The HindIII digested colony PCR amplified products on a 2% agarose gel. A 
band was expected to appear at the area above the thin green line in the event of transgene 
incorporation into the virus genome. 
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With the application of the Gibson Assembly® method, plasmids were constructed 
encoding the CD40L that retained important structural sequences, as confirmed by the 
HindIII and PacI digestions. The freeing of the ITRs following PacI digestion, enabled 
the study to proceed to transfection and primary virus assembly, 
 
7.4  Transfection 
 
Following a round of plasmid propagation in XL10-Gold cells, transfection was 
attempted with ViraPack transfection kit and QIAGEN® Effectene Transfection Reagent. 
For both experiments, around 1 μg of PacI digested plasmids were required of Gibson 
Plasmid 1, Gibson Plasmid 2.1, GFP plasmid, pAd5Δ24, and pAd5/3∆24 found in-house. 
The confirmed digestion of the linearized plasmids used in the ViraPack transfection are 
gathered in Figure 35 and similarly the ones for the QIAGEN® Effectene transfection in 
Figure 36. Only 0.25 μg Gibson Plasmid 2.1 DNA could be added due to low yield after 
digestion and purification. The measured DNA concentrations for the digestions are 
summarized in Table 8. The purity of the samples is also accounted for, the ratio of which 
preferably should be around 1.8 for DNA to be considered pure. 
Figure 35: The PacI digestion of the plasmid DNA used for the ViraPack transfection.  
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Figure 36: The PacI digested Gibson Plasmid 1 and 2.1 in preparation for transfection, 
separated on a 0.8% agarose gel. The plasmids were transfected to A549 cells in T25 
flasks.  
 
Table 8: The measured concentration for the PacI digested DNA for the ViraPack and 
QIAGEN® Effectene reagent transfections after ethanol precipitation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
There are no images for the ViraPack transfection, however, after a week there was still 
no perceivable development of fluorescence in the GFP transfection control nor CPE in 
DNA Concentration 
(ng/μl) 
260/280 Ratio 
ViraPack Transfection 
Gibson Plasmid 1 68.01 1.54 
Gibson Plasmid 2.1 44.87 1.68 
Ad5Δ24 53.27 1.61 
Ad5/3Δ24 20.92 1.61 
QIAGEN® Effectene Transfection Reagent 
Gibson Plasmid 1 648.25 1.47 
Gibson Plasmid 2.1 13.88 1.78 
Ad5Δ24 184.44 1.47 
Ad5/3Δ24 385.78 1.45 
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the virus plasmid transfection. In the QIAGEN® Effectene reagent transfection, 
progressing fluorescence was observed one day after transfection in the GFP control 
(Figure 37). The GFP transfected cells were the only ones monitored for the first five 
days, leaving the cells transfected with viral plasmids in the incubator to minimize cells 
disruption.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37: The green fluorescent protein plasmid transfected A549 cells using the 
Effectene transfection reagent, one and three days after transfection. 
 
After careful monitoring, sufficient CPE was observed in the A549 transfected cells in 
the controls and Gibson plasmids on day 13, whereupon they were harvested. The visual 
state of the cells in the four transfections can be observed at 10X and 20X magnification 
in Figure 38 on page 64. In spite of apparent CPE, recently divided cells can be observed 
in the background of all transfection.  
 
 
  
Day 1 Day 3 
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Figure 38: The state of the transfected A549 cells on the day of harvest, 13 days post 
transfection, in 20X and 10X magnification. Row A: Gibson Plasmid 1 virus, B: Gibson 
Plasmid 2.1 virus, C: Ad5∆24, and D: Ad5/3∆24. 
 
 
20X Magnification 10X Magnification 
A 
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7.5  Immunostaining 
 
Following an amplification round, the virus infected cells were stained using primary and 
secondary antibodies. Infecting the cells with the Gibson Plasmid 1 virus, Gibson Plasmid 
2.1 virus, Ad5/3-hCD40L-CMV, Ad5/3-CD40L-h-TERT, and Ad5Δ24, the A549 were 
fixed using both paraformaldehyde and methanol, 24 and 48 hours after infection. Upon 
staining, the primary antibodies bound to the hexon and CD40L proteins. The proteins 
were finally visualized with secondary antibodies attached with either Alexa 488 or Alexa 
594.  
 
The paraformaldehyde fixed cell stains (24-hour infection) are found in Figure 39 and the 
methanol fixed cells in Figure 40 (24-hour infection) and Figure 41 (48-hour infection). 
In all three figures, the cells are colored blue, green, or red depending on the staining. The 
blue cells are stained with Hoechst to localize the cell nuclei, the green with Alexa 488 
for the CD40L, and the red with Alexa 594 to detect the hexon protein of the Ad capsid. 
 
 
 
 
 
 
66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39: Stained A549 cells fixed with paraformaldehyde 24 hours after infection. The 
Hoechst stained cells locate the cell nuclei, Alexa 488 the CD40L protein, and Alexa 594 
the hexon Ad protein.  
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Figure 40: Methanol fixed A549 cells stained after a 24-hour infection period. The cells 
are located with the Hoechst reagent and the CD40L and hexon protein with the Alexa 
488 and 594, respectively.  
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Figure 41: The methanol fixed A549 cells after a 48-hour infection period. The cell nuclei 
are visualized with Hoechst staining, the CD40L with Alexa 488, and the hexon protein 
with Alexa 594. 
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8  DISCUSSION  
 
The study was a process of trial and error that in the end bore fruit. In the aftermath, a 
template had been established for arming OAds with desirable transgenes. Only one of 
the intended four constructs were successfully generated into a functional virus, however, 
with the established vetted protocols, the remaining constructs are estimated to be 
generated with relative ease. In the following chapter the results and challenges will be 
discussed and compared to available literature in the order of study progression. Possible 
reasons for the failure of the initial method of choice are debated as well as general 
inherent obstacles analyzed. Finally, improvements to the protocol will be contemplated 
and further perspectives for the study considered.  
 
8.1 Genetic Arming of an Oncolytic Adenovirus with CD40L 
 
CRAds have successfully been designed carrying varying transgenes with immune 
system effects. The thesis was planned predicated by encouraging results from previous 
studies proving an antitumor immune response when encoding CD40L into an Ad 
genome, e.g. Ad5/3-hTERT-E1A-hCD40L (Diaconu et al. 2012; Pesonen et al. 2012), 
Ad5-E1/E3-mCD40L (Loskog et al. 2004; Liljenfeldt et al. 2014), and AdEHCD40L 
(Gomes et al. 2009). Additionally, the CD40L has been incorporated alongside other 
transgenes in OVs for co-expression as, for example, in Ad-CCL20-hCD40L which 
possesses several gene expression cassettes: CMVp-CCL20, TERTp-E1A, and E1Bp-
CD40L-IRES-E1B55K (Liu et al. 2015).  
 
The AdEHCD40L was the first study where the CD40L transgene was successfully 
integrated into an OAd vector, utilizing a hypoxia inducing factor (HIF) for selective virus 
activities in HIF-1α–expressing human breast cancer cells (Gomes et al. 2009). The 
Ad5/3-hTERT-E1A-hCD40L has undergone preclinical and clinical studies. The 
preclinical studies proved significant antitumor effects in two syngeneic mouse models, 
whereas the clinical studies provided confirmation of the safety of the virus as well as 
signs of antitumor immunity and efficacy in human patients (Diaconu et al. 2012; 
Pesonen et al. 2012) 
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The novelty of the study was introduced with the soluble CD40L, which to current 
knowledge, has not been encoded in and successfully expressed by an OAd vector. Since 
the full-length CD40L naturally can be cleaved into this soluble form, theoretically there 
would be some present in the previously mentioned studies. However, since this was not 
an object of scrutiny, the extent of cleavage and the consequent ratio between the soluble 
form and full-length remains unknown. In the wake of the thesis, it is still uncertain 
whether the designed soluble CD40L would be excreted from the host cell and whether 
the produced protein folds into the required trimeric form to be biologically active. The 
issue will be addressed in future studies that have been planned as continuations to the 
one presented here.  
 
Homologous recombination is a DNA repair mechanism that has become the preferred 
method generating recombined Ads. Another traditional approach has been to cleave the 
shuttle plasmid and backbone plasmid with restriction enzymes and joining them through 
ligation (He et al. 1998). However, this has proven to have low efficiency for larger 
constructs and is made further difficult by the few suitable unique restriction sites. In the 
generation of recombined OAds with homologous recombination, the AdEasy cloning 
system by Agilent Technologies is widespread and aside from direct application, the 
protocol has been used as a template in the development of other protocols by e.g. 
Hoffmann and Wildner (2006) and Liu and colleagues (2009).  
 
The differences of the plasmids in this study to those in the AdEasy system, as well as the 
chosen area for transgene insertion, prevented complete adherence. Still, the main 
attributes of the commercial protocol could be used as guidelines. The reason(s) as to why 
the widespread approach of homologous recombination failed to yield a recombined 
plasmid in this instance will be explored in further detail in section 8.2.1 on page 72.  
 
8.2  Cloning  
 
Initially, the cloning of the desired virus construct was planned with homologous 
recombination. In the end, the method needed to be switched to Gibson Assembly® for 
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successful transgene insertion, ultimately generating three recombined plasmids though 
slightly varying approaches.  
 
The challenges of the cloning can be traced primarily to the fundamental features of the 
utilized plasmids. Firstly, the sheer size of the final construct constitutes a challenge for 
E. coli. Plasmids below 20,000 bp in size are generally regarded as convenient in cloning. 
Additionally, there is a linear correlation between plasmid size and transformation 
probability in E. coli whereby when the plasmid size increases, the probability decays 
(Hanahan 1983). The final size of the virus construct in this instance would be close to 
40,000 bp, making the laboriousness of recombining the pAd5Δ24-CD40L evident. 
 
There are, however, ways by which the consequences of the construct size can be utilized. 
He and colleagues (1998) reported in their paper that the smaller colonies generally 
represented recombinants. This may be attributed to the fact that the growth of the positive 
colonies is slowed by the size of the recombinant plasmid. This was an approach applied 
to this study, however, the correspondence is uncertain as this potential marker was not 
studiously documented. Consequently, while the ultimately positive colonies were of 
smaller size, they were not necessarily the smallest.   
 
Furthermore, on the issue of size, it has been proposed that the length of the Ad5 genome 
limits the transformation efficiency, a notion promoted by E. coli transformation being 
inhibited by increasing the amount of DNA (Chartier et al. 1996). To enable maintenance 
of a plasmid nearly twice the size of plasmids normally processed, a sufficient incentive 
must be conferred with the large viral plasmid. This is generally achieved by inclusion of 
an antibiotic resistance gene.  
 
Secondly, the plasmids utilized and the location for transgene insertion made a change of 
antibiotic resistance impossible. Altering the antibiotic resistance of the recombined 
plasmid would have considerably facilitated the screening process by reducing the 
amount of background. Instead the subjugation of background colonies was attempted to 
be restrained by plasmid linearization and dephosphorylation which presented its own 
challenges.  
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The pAd5Δ24 was cleaved with EcoRI which was not unique in this plasmid but rather 
caused the excision of a ca 2,700 bp band that was not removed prior to transformation. 
This could enable both the realignment and base-pairing of the band into the vector or the 
recirculation of the digested vector. While the subsequent incubation of the vector with 
CIP enzyme should ameliorate the extent of colonies without the transgene, complete CIP 
digestion cannot be guaranteed, hence the presence of background. Gel purification of the 
vector was an option consciously left unexplored as it was deemed to confer no significant 
advantage as even without it there ought to be some positive clones. Double digestion 
with SpeI and EcoRI was later applied to improve on this aspect of the protocol.   
 
Thirdly and finally, an issue relevant for the failed homologous recombination was the 
presence of superfluous homologous regions aside from the ones flanking the E3-gp19K. 
Generating a risk for erroneous recombination and the potential loss of critical elements 
in the rescue plasmid, this constituted a major obstacle for successful recombination. This 
problem will be explored in detail in section 8.2.1 on page 74.  
 
The three aforementioned challenges were perceived at the beginning of the project and 
were in the extent possible accommodated, e.g. with the use of an E. coli strain with larger 
construct capacity (XL10-Gold) and CIP enzyme incubation with the backbone plasmid. 
Other aspects of the study which could not be altered involved changing the backbone 
plasmid and the location of transgene insertion. Ultimately, the only major component 
which could be modified would be to exchange the pTHSN for another shuttle plasmid, 
an option that will be explored further at a later point in this chapter.   
 
Regarding the XL10-Gold bacteria, the application of the strain was later debated as a 
bacteriophage contamination was discovered upon sequencing of the backbone plasmid 
near the end of the study.  In a letter to the editor, Kamal et al. (2013) describe a similar 
issue, however, no other mentions were found on the matter. Therefore, it was also 
considered that the contamination could have stemmed from the working environment. 
In terms of impact on the study, a contamination would at least be a disturbing element, 
at worst cause the destruction of bacteria carrying the recombined plasmid. The matter 
would require further investigation and the possible application of another bacterial strain.  
73 
 
8.2.1. Homologous Recombination  
 
The principle for the AdEasy system was published by He and colleagues in the year 
1998. The study details a strategy that enables recombination of SC Ad vectors by 
utilizing the inherent homologous recombination machinery in E. coli, allowing the 
inclusion of a maximum of 10,000 bp foreign DNA as well as multiple transgene 
expression. Prior to the publication of the study, manipulation of the Ad genome required 
utilization of restriction enzyme sites for gene insertion and mammalian cells for 
recombination, an approach that aside from being time-consuming and laborious was also 
hindered by the few applicable restriction enzyme sites in the Ad genome. The 
development of the strategy by He and colleagues (1998) additionally provided a means 
for facilitated direct evaluation of transfection and infection efficiency by the 
incorporation of a GFP gene into the Ad backbone sequence. The principles of the 
developed double-transformation, or cotransformation, technique presented in their study 
is echoed to an extent in this study.  
 
Almost a decade later, Luo et al. (2007) introduced a modification to the protocol by He 
et al. (1998) whereby the Ad vector is first transformed into BJ5183 cells with 
electroporation. Growing the bacteria in the presence of antibiotics, the Ad vector 
transformed bacterial colonies are identified and cultured. Afterward, the bacteria are 
made chemically competent before transformation of the linearized shuttle plasmid into 
the cells with heat shock. Finally, the transgene is transferred into the virus backbone with 
the aid of homologous regions.  
 
The main differences in the studies by He et al. (1998) and Luo et al. (2007) to the one 
presented here, was the insertion of the whole shuttle plasmid into the backbone vector. 
Aside from the gene of interest, the shuttle plasmid provides altered antibiotic resistance, 
origin of replication, the left ITR, and two PacI restriction enzyme sites. The change in 
antibiotic resistance eliminates the need for linearization and CIP digestion of the 
backbone plasmid, instead enabling its transformation in SC form, which has improved 
transformation probability (Hanahan 1983).  
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The method in the AdEasy cloning system could not be directly applied as it fails to allow 
targeted insertion of the gene of interest into the E3 region of the Ad genome, a crucial 
requirement for this study. The transgene insertion into the backbone also prevents the 
utilization of other potential markers for positive clones, such as the lacZ gene. 
Additionally, transforming pAd5Δ24 to the BJ5183 cells first, the linearized pTHSN-
CD40L confers no added benefit to the bacteria, therefore providing no incentive for the 
bacteria to recombine the transgene into the virus backbone, thus failing to improve upon 
the situation. 
 
An important fact to consider in contemplating the failure of the homologous 
recombination was the presence of superfluous homologous regions, which was briefly 
touched upon previously. A sequence comparison with the Basic Local Alignment Search 
Tool developed by Altschul and colleagues (1997) of the empty pTHSN and the pAd5Δ24 
revealed that there are four regions with moderate to high alignment. The results of the 
search are presented in Figure 42.  
                                                         
Figure 42: The results from Basic Local Alignment Search Tool by Altschul and 
colleagues (1997) of the pAd5Δ24 and pTHSN. According to the color key alignment 
scores, there are three areas with high alignment between pAd5Δ24 and empty pTHSN 
(1, 3, and 4), and one small visible area (2) that has a slightly lower alignment score.  
 
The location of these homologous regions in relation to other vital elements of the 
pAd5Δ24 genome is presented in Figure 43. As is depicted, the largest homologous region 
is in the E3 transcription unit. From this area a ca 2,700 bp fragment is excised with EcoRI 
digestion, leaving homology regions around 250 bp and 1,000 bp in size in the middle of 
which the transgene will be inserted. The remaining three areas are all located close to 
the PacI digestion sites and ITRs. 
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Figure 43: The pAd5Δ24 genome linearized and magnified. The homologous region 
marked in green was the area into which the transgene would be inserted. The wine-red 
areas marked with an ‘X’ adjacent to the PacI sites are superfluous regions with homology 
between the pTHSN and the pAd5Δ24. The image was made in SnapGeneViewer.  
 
The recognition sequences for both PacI digestion sites by the ITRs are separated by ca 
15 bp from the superfluous regions with homology. Restriction analysis of potential 
positive clones from homologous recombination proved that one PacI site was retained 
in this area since the vector was successfully cleaved, though the absence of an excised 
band indicated the incomplete freeing of the ITRs. Narrowing down which of the two 
sites might have undergone sequential changes can be aided by the BamHI restriction 
enzyme reactions. 
 
One BamHI recognition site is located closed to the PacI site by the left ITR. Changes to 
the sequence affecting PacI digestion are likely to also impact BamHI digestion and can 
therefore be used as a marker. On two of the gel run samples (Figure 23 on page 58, lane 
8 and 10) there are two visible bands. Upon comparing them with the controls and the 
size marker, the bands appear to be around 24,000 bp and 7,000 bp in size. Successful 
integration of the transgene should yield three bands ca 7,000 bp, 7,300 bp, and 24,000 
bp in size. Due to the two smaller bands being relatively close in size and the weak 
intensity of the band on the gel, it may be that the final band is simply not visible, or 
overlapping with the ca 7,000 bp band. In the end, it remains inconclusive whether the 
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BamHI site, and consequently the closest PacI site, has disappeared. Aside from the four 
major homologous regions, an additional nine areas were identified that albeit small (the 
largest of them 51 bases, not shown) may cumulatively have disturbed the vector integrity 
to the extent that a functional virus would have been unable to be constructed.  
 
It was acknowledged that the prolonged maintaining of the plasmids in the BJ5183 cells 
was a mistake during the first homologous recombination attempt. While the metabolism 
and inner machinery of the bacteria should be reduced when the LB plates were stored at 
4 ˚ C, it is possible that the bacteria continued to modify a potentially recombined plasmid. 
This is further validated by the extensive background and disproportion of the bands in 
the PacI, BamHI, and HindIII digestions in Figure 22 and 23 (page 55). It is likely, that 
the bacteria have modified the pTHSN (a much more manageable plasmid) by utilizing 
the homologous sequences flanking the kanamycin resistance gene, either switching the 
antibiotic resistance gene into the shuttle plasmid or generating an intermediate between 
the recue and shuttle plasmid with only the most essential elements for survival.  
 
To remedy this issue, the duration between transformation and screening was reduced 
during the second attempt, along with double digestion of the pTHSN with SpeI and NdeI. 
As a result of the double digestion, the transgene, and the flanking homologous regions 
would be excised from the shuttle plasmid. However, no further isolation or purification 
of the fragment from remaining pTHSN was done aside from ethanol precipitation. This 
upon the advice of the article by Luo et al. (2007), according to whom gel purification of 
the cleaved shuttle should be avoided in order to prevent nicking the DNA as well as the 
reduction of transformation efficiency. While the pTHSN fragments may not in 
themselves constitute a major background component after transformation, it nonetheless 
brings a disturbing element to the transformation and recombination, reducing efficiency.  
 
In the end, the one major change that might have considerably improved the outcome of 
homologous recombination would have been the changing of shuttle vectors to one 
without superfluous homology. Other minor changes suggested by Luo et al. (2007) not 
implemented would be reduction of incubation time post transformation from over an 
hour to 30 minutes or even excluding it all together and an increase of the kanamycin 
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concentration from 25 μg/ml to 50 μg/ml, at least for the LB-plates. Furthermore, while 
the authors recommend abstaining from gel purification, the shuttle plasmid conferring 
could be purified with alkaline lysis miniprep procedure in the event of too many colonies 
following transformation, a suggestion which could be attempted for the rescue plasmid 
in this study. 
 
8.2.2  Gibson Assembly® 
 
Gibson Assembly® is an alternative to recombination proficient bacteria. A simplified in 
vitro approach, principle for this isothermal recombinant DNA method was first presented 
in a 2008 paper by Gibson and colleagues titled “Complete Chemical Synthesis, 
Assembly, and Cloning of a Mycoplasma genitalium Genome”. Later, the method for the 
isothermal single-reaction was published separately (Gibson et al. 2009). The idea that 
the Gibson Assembly® reaction builds upon is very simple and while the approach may 
be very straightforward it still has its own challenges.  
 
The most relevant challenges for the approach presented here is, once more, the size of 
the construct. With the Gibson Assembly® DNA fragments as large as ca 150,000 bp was 
successfully cloned in E. coli in a two-step reaction (Gibson et al. 2008). The method has 
also been successfully applied in the synthesis of artificial bacterial cells (Gibson et al. 
2010). Depending on the size of the fragments, the Synthetic Genomics, Inc Company 
Gibson Assembly® cloning guide, recommends either a one- or two-step reaction. For 
DNA ranging between 500 bp to 32,000 bp in a reaction of at most five fragments, the 
maximum construct size is 100,000 bp in multi-stage reactions. No published studies 
could be found where an OAd vector had previously been cloned in the manner reported 
here where an almost 40,000 bp construct has been generated in a single two fragment 
reaction.  
 
The protocol with Gibson Assembly®, while successful, still left room for optimization. 
Currently, the success rate was at 4%, calculated from the number of positive colonies to 
the total number screened. Two major changes have been planned for future reactions, 
the first one being creating longer overlaps. Primers with 40 bp, 60 bp, and 80 bp overlaps 
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have already been designed for future use, their length providing a higher specificity. The 
second change would be the incubation period of the reaction. According to Gibson and 
colleagues (2009), 60 minutes was deemed an optimal duration, and in this instance 
prolonging the time from 15 minutes to 60 minutes would enable more of the desired 
construct to form.  
 
After transformation to XL10-Gold cells, the study reactions and controls were plated 
onto LB plates with either kanamycin or ampicillin. The positive control provided with 
the Gibson Assembly® kit yielded expected results in the form of bacterial colonies 
growing on LB-ampicillin plates. However, the intended negative control behaved 
unexpectedly by also producing bacterial colonies. It was assumed that the mismatched 
transgene containing fragment would prevent plasmid propagation. Based on the apparent 
survival of bacteria under kanamycin selection, either the EcoRI restriction digestion or 
the dephosphorylation must have been incomplete. Despite this, the correct construct was 
still able to form in the Gibson reaction combining the EcoRI digested backbone with the 
correct corresponding PCR fragment (Gibson Reaction 2).  
 
8.2.3  Screening of Colonies  
 
Aside from improvements to the methods applied in the presented study, the screening 
and verification process of the clones was another object of scrutiny. The restriction 
analyses were always performed with internal controls to confirm the correct function of 
the enzymes in use and there was no doubt as to their functionality at the employed 
conditions. The lack of selection markers placed increased significance on an efficient 
screening method.  
 
Overall, the established colony PCR protocol performed consistently and robustly with 
appropriate adjustments and optimizations made during the study. The primers utilized 
were designed to bind to DNA outside the transgene sequence, enabling the employment 
of the same primer pair for all intended constructs. The CD40L transgenes is in full-length 
around 200 bp smaller than the E3-gp19k it displaces, 786 bp (human) or 783 bp (mouse) 
and 986 bp respectively. The soluble CD40L is even smaller, only 510 bp. Since the 
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empty and recombined pAd5Δ24 both produce a signal, a way to distinguish between 
them is by comparing the sizes of the PCR fragments. With a sufficiently high agarose 
content, the size differences between the recombined and empty backbone plasmids 
should be discernable. Another approach would be to design primers where one binds to 
the transgene sequences. This provides more substantial proof that any positive colony 
contains the transgene and reduces the risk for false positives. 
 
Incorporating colony PCR into the screening process was advocated by the method 
having a high throughput capacity, allowing for the analysis of a large number of colonies 
in a relatively short time-frame. Colony PCR is a staple in molecular cloning as an 
efficient and robust screening method of transformed and selected bacteria. One 
advantage of colony PCR the possibility to screen bacteria without the need for further 
bacterial amplification. In fact, less is more regarding DNA in colony PCR. The colony 
PCR reactions were always run alongside positive and negative controls that performed 
consistently according to expectations. The functionality of the primers was even at one 
point studied with a gradient PCR to affirm the correct annealing temperature for the PCR 
cycle (Figure 44). For this experiment, the bacterial solution was diluted 1:3 in MQ, 
adding 20 μl of the dilution to the master mix.  
 
Figure 44: Gradient colony PCR results using pAd5Δ24 transformed XL10-Gold as 
template. The temperature ranged from 54.2 ˚C to 58.0 ˚C. 
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Utilizing DreamTaq DNA polymerase, the calculated annealing temperature was 53 ˚C 
which corresponded quite well with the PCR analysis which suggested the maximum 
PCR product being generated at ca 51.9 ˚C (lane 6). The bacteria carrying the screened 
pAd5Δ24 plasmid, XL10-Gold, was also added to the screen to provide unequivocal 
proof that there was nothing in the bacteria to which the primers could bind and produce 
a PCR product. The gradient PCR echoed previous results gained with gradient PCR 
using isolated plasmid DNA as template (results not shown). 
 
The gradient PCR also highlighted an issue with the dephosphorylated and cut pAd5Δ24 
vector. Theoretically, there should be no signal from the control since successful enzyme 
digestion would remove the binding site for the reverse primer (Primer Set II reverse). A 
religated EcoRI digested pAd5Δ24 would similarly lack the binding site for the reverse 
primer, hence generating no PCR amplified product. However, this was not the case and 
instead either a PCR fragment was observed (pAd5Δ24 SC and pAd5Δ24-EcoRI-CIP) in 
substantial quantities or nothing was generated as was the case for the majority of the 
screened colonies. LB has the ability to inhibit the PCR process, but insufficient dilution 
was excluded as a reason since it was verified to function with positive controls (the 
empty pAd5Δ24 SC). This result does, nonetheless, confirm earlier suspicions of 
incomplete vector digestion and/or dephosphorylation as previously discussed regarding 
the “negative” control to the Gibson Assembly® (page 78).  
 
In the colonies transformed with the Gibson Assembly® products, the lack of signal can 
also be explained by the fact that the exonuclease has simply eaten away the area to which 
the primers would bind, hence no product being formed. To reduce this type of 
background, it was considered that the reaction volume may be too large (100 μl) in the 
EcoRI digestion. In this case, the digestion could benefit from reducing the volume to 
multiple 50 μl reactions, similarly halving the DNA amount and enzyme amount to 1 μl 
of enzyme and 5 μg DNA. This approach was adopted for the PacI digestion prior to 
transfection, afterwards pooling two 5 μg reactions into one. It was also attempted for the 
EcoRI digestion of 10 μg of the backbone plasmid in the 50 μl reaction volume. Since the 
primers produced signals for the digested and dephosphorylated backbone, a reduction in 
DNA may generate more complete digestion of all DNA.  
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8.3  Transfection 
 
In the in vitro propagation of viruses, there are certain cell lines that are used (Wold & 
Ison 2013). The cell line regarded as perhaps the most ideal host for all human Ad is the 
primary human embryonic kidney (HEK) cells. However, because of sequence 
homology, a low frequency of recombination has been identified in HEK293 cells 
between the DNA of the Ad in the cell line and transfected E1-deleted vectors. 
Consequently, replication-competent Ads will be generated in replication-deficient stock. 
By utilizing the A549 cell line, the risk of generating Ad5 with a fully intact E1 region 
should not be an issue.   
 
In the transfection with the ViraPack kit, the experiment was deemed a failure when there 
was no development of GFP after six days of incubation aside from the auto-fluorescence 
of dead cells. While the CPE can take longer to manifest, the fluorescence should develop 
during the first couple of day. An explanation for the negative result may be the 
insufficient amount of DNA, which was something that constituted a challenge. While 10 
μg DNA was digested in two 5 μg reactions before pooling them and precipitating the 
DNA with ethanol, the DNA concentrations as well as the purity of the DNA solutions 
were low which would have impacted the chances of successful transfection (Table 8, 
page 62).  
 
The AdEasy system presents a modified protocol for transfection with the ViraPack kit 
where after DNA addition the cells are incubated for 3 hours before aspiration. The 
replacing media is supplemented with 25 μM chloroquine and incubated anew for an 
additional 6-7 hours before removal and addition of complete medium. Other 
optimization steps to the protocol is changing the concentration of the modified bovine 
serum. In the transfection performed during this study, the culture medium contained 6% 
bovine serum which was the recommended starting point by the manufacturer 
(APPENDIX 8) in a concentration range of 4-7%. Due to time constraints, it was decided 
to abandon optimization of the protocol in favor of trying the QIAGEN® Effectene 
Transfection Reagent.  
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8.4 Immunostaining 
 
The QIAGEN® Effectene Transfection Reagent transfected cells were initially seeded 
into the wells of a 12-well plate. Curiously, the cells seemed to be dying and were 
adhering poorly to the surface of the coverslips, even after a 24-hour incubation. While 
no viable cause was found, it was speculated that the coverslips may have been coated 
with an agent that was harmful to the cells such as residual alcohol that had failed to 
evaporate. The cells, visibly recuperated after the changing of the media (complete 
DMEM) of the same batch that they had previously been in and the event was deemed 
inconsequential to the outcome of the staining.  
 
In the first round the cells were fixed 24 hours after infection with paraformaldehyde and 
methanol. Upon comparison of the different fixation methods, it became apparent that the 
methanol fixed cells were stained better than the paraformaldehyde fixed cells. This may 
be attributed to the fact that the methanol was more successful at permeabilizing the cells, 
allowing for better binding of the subsequent primary and secondary antibodies. 
Throughout, the perhaps hardest stains to elucidate were those of the CD40L. To 
differentiate between auto-fluorescence and the actual expression of the CD40L 
transgene, the location of the observed fluorescence was scrutinized. Auto-fluorescence 
from e.g. dead cells would appear as bright fluorescing patches of the same intensity 
allover. The CD40L being a transmembrane protein led to the assumption that the 
antibodies would concentrated to the outer rim of the cell and to the nucleus. This was 
confirmed with the visualization of the Alex 488 in the methanol permeabilized cells 
infected for 48 hours with the viruses from Gibson Reaction 1 and 2 (Figure 41 page 68).   
 
In an attempt to further enhance the signal for the CD40L, the infection was prolonged 
from 24 hours to 48 hours. While this did successfully enhance the fluorescence, it was 
still not as clear as the hexon staining. As can be seen in Figure 45 on the following page, 
there is a unique “halo effect” without a filter that occurs for some of the double positive 
stained cells. This effect as not observed for the Ad5Δ24 or other controls and may be a 
marker for cells expressing the CD40L. However, this would require further studies to 
confirm. 
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Figure 45: Cells infected with the Gibson Plasmid 1 virus (left) and Gibson Plasmid 2.1 
virus (right) fixed with methanol 48 hours after infection. A peculiar halo effect seems to 
appear for some of the cells positive for both Ad hexon and CD40L protein. The same 
effect was absent from the other control infections.  
 
Generally, the weakness of the CD40L staining can be attributed to several reasons that 
ascribe to either the antigen or antibody. Low expression of the CD40L would result in 
lower levels of antigen for the antibodies to bind to. Similarly, the concentration of the 
antibody may be too dilute. The cause deemed the most credible was the secondary 
antibody not being ideal for use with this primary antibody. Still, with the lack of a 
functional positive control for the CD40L, the functionality of the antibodies could not 
be reliably evaluated in this experiment. Unequivocal proof of the presence of the CD40L 
protein could be obtained by Western blot or an ELISA assay. For the Ad5Δ24-CD40L 
of the soluble variants, Ramos-Blue™ cells were intended to be applied for the 
determination of levels of e.g. CD40L.  
 
Another issue warranting speculation was the stained cells that showed high levels of the 
hexon protein and thus the OAd but were not positive for the CD40L. The virus capsid 
component production occurs during the late stages of the virus proliferation around the 
same time the encoded transgene protein should be expressed. The negative controls were 
clean in all instances while the Ad5Δ24 virus control gave a clear signal which coincided 
with the signal found for the two generated viruses. However, the positive controls for 
the CD40L, i.e. Ad5/3-hCD40L-CMV and Ad5/3-CD40L-h-TERT, were lackluster. 
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Since the behavior of these viruses was consistent, it is highly possible that there was a 
problem with these vials or the batch of viruses.  
 
8.5 Future Perspectives 
 
Upon revisiting the initial aims laid out for the thesis, all three were largely fulfilled, 
albeit only for one virus. The construction of the remaining viruses will hopefully proceed 
without major complications, after which, the objective would be virus amplification and 
cesium chloride or kit purification. Regarding determination of the virus titer, while not 
addressed in the study, the titer for the produced Ad5Δ24-hCD40L-FL viruses was 
performed with spectrophotometry. However, since the reliability of the results could not 
be verified in the allotted time, the results were not included. Therefore, future efforts 
would entail the reliable determination of the virus titer for all the generated viral 
preparations with plaque assay.  
 
In contemplating other future perspectives of the designed viruses, the first priority would 
be to gather sufficient evidence of functionality and efficacy of the generated viruses in 
vitro. This includes the verification of the CD40L expression and functionality as 
costimulatory molecules, particularly for the soluble CD40L. How well the soluble and 
full-length CD40L constructs stimulate the immune system and whether one is more 
effective than the other, is particularly interesting. 
 
In the event that the soluble CD40L encoded construct proves more adapt at eliciting a 
strong antitumor response, the next major step would be proceeding to in vivo studies 
with humanized mice carrying melanoma tumors. Having mice with a human immune 
system is preferable as it is as close to a human test subject the viruses can be studied in 
at this point of development. Melanoma enables easy intratumoral injection because of 
its palpable tumor mass. Because of it is a more immunogenic form of cancer, it is also a 
suitable model for therapies wherein immune stimulation is a fundamental aspect of the 
study. The experiment would further be critical in determining the potential of the 
Ad5Δ24-mCD40L viruses, since if the treatment fails in this model, there is little hope of 
them working on any other cancer.  
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9  CONCLUSIONS  
 
Cancer persistently afflicts a growing part of the world population, with several million 
people being diagnosed annually. In the search of new and efficient treatments, the 
oncolytic viruses have emerged as a field in oncology beginning to yield results. The 
study presented here delves into traditional and novel methods of cloning to generate a 
CD40L armed oncolytic adenovirus with the intent to enhance the elicitation of systemic 
antitumor immunity. Ultimately, a functional Ad5Δ24-hCD40L-FL virus was generated 
with confirmed transgene expression using Gibson Assembly® in manner previously 
unreported. Consequently, protocols were successfully established to the laboratory for 
future purposes, encompassing the main steps from cloning to primary virus production. 
The protocols can be further be applied for the construction of an Ad5Δ24 with insertion 
of transgenes aside from the CD40L. Considering the discussed improvements to the 
protocols, future perspectives of the presented study encompass the generation of the 
remaining viruses, including the viruses encoding the novel soluble CD40L transgenes. 
After in vitro validation of expression and functionality of all the transgenes as well as 
virus stock production and titer determination, the study will hopefully proceed to in vivo 
testing.  
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APPENDICIES 
 
APPENDIX 1: The CD40L amino acid sequences and design 
 
The CD40L was designed in a membrane bound and soluble form. The intra-, trans-, and 
extracellular domain of the membrane bound form are depicted by the three different 
colors utilized: blue (extracellular), yellow (transcellular), and brown (extracellular). The 
total length of the membrane bound form is 261 (human) or 260 (mouse) amino acids.  
 
 
 
After the molecular processing, the 149 aminoacid sequence for the soluble CD40L is 
generated. To ensure the secretion of this soluble form, a 20 amino acids long signal 
peptide was added to the N-terminal.   
 
 
 
 
UniProtKB 
Homo sapiens (Human) CD40L_HUMAN Length 261 
A. Topology  
 
 
Feature key Position(s) DescriptionActions Length 
Topological 
domain 
1 – 22 Cytoplasmic 22 
Transmembrane 23 – 46 Helical; Signal-anchor for type II 
membrane protein 
24 
Topological 
domain 
47 – 261 Extracellular 215 
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B. Immature sequence  
Length 261  Mass (Da) 29,274 
 
 
C. Molecule processing 
 
 
 
 
 
 
Mus musculus (Mouse) CD40L_MOUSE Length 260 
A. Topology 
 
   10         20         30         40         50 
MIETYNQTSP RSAATGLPIS MKIFMYLLTV FLITQMIGSA LFAVYLHRRL  
        60         70         80         90        100 
DKIEDERNLH EDFVFMKTIQ RCNTGERSLS LLNCEEIKSQ FEGFVKDIML  
       110        120        130        140        150 
NKEETKKENS FEMQKGDQNP QIAAHVISEA SSKTTSVLQW AEKGYYTMSN  
       160        170        180        190        200 
NLVTLENGKQ LTVKRQGLYY IYAQVTFCSN REASSQAPFI ASLCLKSPGR  
       210        220        230        240        250 
FERILLRAAN THSSAKPCGQ QSIHLGGVFE LQPGASVFVN VTDPSQVSHG  
       260  
TGFTSFGLLK L                                  
Position(s) Description Actions Length 
1 – 261 CD40 ligand, membrane form 261 
113 – 261 CD40 ligand, soluble form 149 
Feature key Position(s) Description Actions Length 
Topological 
domain 
1 – 22 Cytoplasmic 22 
Transmembrane 23 – 46 Helical; Signal-anchor for type II 
membrane protein 
24 
Topological 
domain 
47 – 260 Extracellular 214 
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B. Immature sequence 
Length 260   Mass (Da) 26,370  
 
C. Molecule processing 
 
Position(s) Description Actions Length 
1 – 260 CD40 ligand, membrane form 260 
112 – 260 CD40 ligand, soluble form 149 
 
 
 
 
 
 
 
 
 
        10         20         30         40         50 
MIETYSQPSP RSVATGLPAS MKIFMYLLTV FLITQMIGSV LFAVYLHRRL  
        60         70         80         90        100 
DKVEEEVNLH EDFVFIKKLK RCNKGEGSLS LLNCEEMRRQ FEDLVKDITL  
       110        120        130        140        150 
NKEEKKENSF EMQRGDEDPQ IAAHVVSEAN SNAASVLQWA KKGYYTMKSN  
       160        170        180        190        200 
LVMLENGKQL TVKREGLYYV YTQVTFCSNR EPSSQRPFIV GLWLKPSSGS  
       210        220        230        240        250 
ERILLKAANT HSSSQLCEQQ SVHLGGVFEL QAGASVFVNV TEASQVIHRV  
       260 
GFSSFGLLKL                                              
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APPENDIX 2: Preparation for Gibson Assembly® 
 
The transgene insert production 
The PCR cycle and master mix composition for amplification of the PCR insert in Gibson 
Assembly® 
 
PCR cycle: 
98 °C 20 s 
98 °C 10 s      
57 °C 20 s              30 cycles 
72 °C 90 s      
72 °C 5 min 
12 °C ∞ 
 
 
 
Backbone digestion 
 
The backbone was single (EcoRI-HF) and double digested (SpeI and EcoRI)  
 
MQ to 50 μl 
5 μl 10x Cutsmart buffer 
10 μg pAd5D24  
2 μl EcoRI HF/ SpeI  
 
Incubate at 37 °C for 1 hr. Confirm digestion on 0.8 % agarose gel run at 70 V for 1 hr. 
Heat-inactivate the digestions for 20 minutes at a minimum of 80 °C 
  
 
 
 
 
 
 
 
 
 
 
FINAL 
CONC. 
REAGENT 
to 50 μl MQ 
1x 5x Phusion HF Buffer  
0.5 μM Gibson Reaction Forward primer 
0.5 μM Gibson Reaction Reverse primer 
1 ng pTHSN-CD40L-human 
0.2 mM 10 mM dNTPs mix 
3% DMSO 
0.02 U/μl Phusion DNA Polymerase 
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APPENDIX 3: Colony Polymerase Chain Reaction 
 
 
The day after the transformation, pick colonies for minipreps and grow them overnight. 
The following morning, the template can be processed in two ways: 
1) Take 5 μl of the bacterial solution and dilute it in 95 μl MQ before boiling it at 98 
°C for 10 minutes in the thermal cycler. 20 μl of the dilution is then used for the 
PCR. 
2) Add 30 μl bacterial culture to 70 μl MQ and use 20 μl of this dilution for the PCR. 
 
In both cases, add 30 μl of the master mix with half the volume of MQ to compensate for 
the MQ added with the template. 
 
DreamTaq 
 
PCR cycle: 
95 °C 2 min 
95 °C 30 s 
58 °C 30 s               30 cycles 
72 °C 2 min 
72 °C 5 min 
4 °C  ∞ 
 
 
Run the PCR amplified products on 1.5 % agarose gels for 1 hr at 70 V. 
 
Phusion HF 
 
PCR cycle: 
98 °C 3 min 
98 °C 10 s 
66 °C 20 s               35 cycles 
72 °C 30 s 
72 °C 5 min 
6 °C ∞ 
 
 
 
 
 
 
 
 
FINAL CONC. REAGENT 
to 50 μl x 0,5 MQ 
1x 10X DreamTaq Buffer 
0.5 μM Forward Primer 
0.5 μM Reverse Primer 
0.2 mM 10 mM dNTP Mix 
1.25 U DreamTaq DNA Polymerase 
20 μl  Template in MQ 
FINAL CONC. REAGENT 
to 50 ul x 0,5 MQ 
1x 5X Phusion HF Buffer  
0.5 μM Forward Primer 
0.5 μM Reverse Primer 
0.2 mM 10 mM dNTP Mix 
0.02 U/μl Phusion DNA Polymerase 
20 μl  Template in MQ 
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APPENDIX 4: Protocol for QIAGEN® Plasmid Mini Kit 
 
This is the plasmid extraction protocol as provided by the manufacturer for the 
QIAGEN® Plasmid Minikit (ref no: 12123). 
 
Procedure 
1. Pick a single colony from a freshly streaked selective plate and inoculate a starter 
culture of 2–5 ml LB medium containing the appropriate selective antibiotic. 
Incubate for approximately 8 h at 37°C with vigorous shaking (approx. 300 rpm). 
Use a tube or flask with a volume of at least 4 times the volume of the culture. 
 
2. Dilute the starter culture 1/500 to 1/1000 into 3 ml selective LB medium. Grow at 
37°C for 12–16 h with vigorous shaking (approx. 300 rpm). Use a flask or vessel with 
a volume of at least 4 times the volume of the culture. The culture should reach a cell 
density of approximately 3–4 x 109 cells per milliliter, 
which typically corresponds to a pellet wet weight of approximately 3 g/liter medium.,  
 
3. Harvest the bacterial cells by centrifugation at 6000 x g for 15 min at 4°C. 
If you wish to stop the protocol and continue later, freeze the cell pellets at –20°C. 
 
4. Resuspend the bacterial pellet in 0.3 ml of Buffer P1. 
Ensure that RNase A has been added to Buffer P1. If LyseBlue reagent has been added 
to Buffer P1, vigorously shake the buffer bottle before use to ensure LyseBlue particles 
are completely resuspended. The bacteria should be resuspended completely by vortexing 
or pipetting up and down until no cell clumps remain. 
 
5. Add 0.3 ml of Buffer P2, mix thoroughly by vigorously inverting the sealed tube 
4–6 times, and incubate at room temperature (15–25°C) for 5 min. 
Do not vortex, as this will result in shearing of genomic DNA. The lysate should appear 
viscous. Do not allow the lysis reaction to proceed for more than 5 min. After use, the 
bottle containing Buffer P2 should be closed immediately to avoid acidification from CO2 
in the air. If LyseBlue has been added to Buffer P1, the cell suspension will turn blue after 
addition of Buffer P2. Mixing should result in a homogeneously colored suspension. If 
the suspension contains localized colorless regions or if brownish cell clumps are 
still visible, continue mixing the solution until a homogeneously colored suspension is 
achieved. 
 
6. Add 0.3 ml of chilled Buffer P3, mix immediately and thoroughly by vigorously 
inverting 4–6 times, and incubate on ice for 5 min. 
Precipitation is enhanced by using chilled Buffer P3 and incubating on ice. After addition 
of Buffer P3, a fluffy white material forms and the lysate becomes less viscous. The 
precipitated material contains genomic DNA, proteins, cell debris, and KDS. The lysate 
should be mixed thoroughly to ensure even potassium dodecyl sulphate precipitation. If 
the mixture still appears viscous, more mixing is required to completely neutralize the 
solution. If LyseBlue reagent has been used, the suspension should be mixed until all 
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trace of blue has gone and the suspension is colorless. A homogeneous colorless 
suspension indicates that the SDS has been effectively precipitated.  
 
7. Centrifuge at maximum speed in a microcentrifuge for 10 min. Remove 
supernatant containing plasmid DNA promptly. 
Before loading the centrifuge, the sample should be mixed again. Centrifugation should 
be performed at maximum speed in 1.5 ml or 2 ml microcentrifuge tubes (e.g., 10,000–
13,000 rpm in a microcentrifuge). Maximum speed corresponds to 14,000–18,000 x g for 
most microcentrifuges. After centrifugation, the supernatant should be clear. If the 
supernatant is not clear, a second, shorter centrifugation should be carried out to avoid 
applying any suspended or particulatematerial to the column. Suspended material (which 
causes the sample to appear turbid) will clog the column and reduce or eliminate flow. 
 
Optional: Remove a 50 μl sample from the cleared lysate and save it for an analytical 
gel (sample 1). 
 
8. Equilibrate a QIAGEN-tip 20 by applying 1 ml Buffer QBT, and allow the column 
to empty by gravity flow. 
PlaceQIAGEN-tips into aQIArack over the waste tray or use the tip holders provided with 
each kit (see “Setup of QIAGEN-tips” page 13). Flow of buffer will begin automatically 
by reduction in surface tension due to the presence of detergent in the equilibration buffer. 
Allow the QIAGEN-tip to drain completely. QIAGEN-tips can be left unattended, since 
the flow of buffer will stop when the meniscus reaches the upper frit in the column. 
 
9. Apply the supernatant from step 7 to the QIAGEN-tip 20 and allow it to enter the 
resin by gravity flow. 
The supernatant should be loaded onto the QIAGEN-tip promptly. If it is left too long 
and becomes cloudy due to further precipitation of protein, it must be centrifuged again 
before loading to prevent clogging of the QIAGEN-tip. 
 
Optional: Remove a 50 μl sample of the flow-through and save for an analytical gel 
(sample 2). 
 
10. Wash the QIAGEN-tip 20 with 2 x 2 ml Buffer QC. 
Allow Buffer QC to move through the QIAGEN-tip by gravity flow.  
 
Optional: Remove a 220 μl sample of the combined wash fractions and save for an 
analytical gel (sample 3). 
 
11. Elute DNA with 0.8 ml Buffer QF. 
Collect the eluate in a 1.5 ml or 2 ml microcentrifuge tubes (not supplied). 
Note: For constructs larger than 45–50 kb, prewarming the elution buffer to 65°C may 
help to increase yield. 
Optional: Remove a 45 μl sample of the eluate and save for an analytical gel (sample 4).  
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12. Precipitate DNA by adding 0.7 volumes (0.56 ml per 0.8 ml of elution volume) of 
room-temperature isopropanol to the eluted DNA. Mix and centrifuge immediately 
at ≥15,000 x g rpmfor 30min in amicrocentrifuge. Carefully decant the supernatant. 
All solutions should be at room temperature to minimize salt precipitation. Isopropanol 
pellets have a glassy appearance and may be more difficult to see than the fluffy, salt-
containing pellets that result from ethanol precipitation. Marking the outside of the tube 
before centrifugation allows the pellet to be easily located. Isopropanol pellets are also 
more loosely attached to the side of the tube, and care should be taken when removing 
the supernatant. 
 
13. Wash DNA pellet with 1 ml of 70% ethanol and centrifuge at 15,000 x g for 10 
min. Carefully decant the supernatant without disturbing the pellet. 
The 70% ethanol removes precipitated salt and replaces isopropanol with the more 
volatile ethanol, making the DNA easier to redissolve. 
 
14. Air-dry the pellet for 5–10min, and redissolve the DNA in a suitable volume of 
buffer (e.g., TE buffer, pH 8.0, or 10mM Tris·Cl, pH 8.5) 
Redissolve the DNA pellet by rinsing the walls to recover the DNA. Pipetting the DNA 
up and down to promote resuspension may cause shearing and should be avoided. 
Overdrying the pellet will make the DNA difficult to redissolve. DNA dissolves best 
under slightly alkaline conditions; it does not easily dissolve in acidic buffers. 
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APPENDIX 5: Restriction analysis and digestions 
 
pTHSN-CD40L, all constructs  
MQ to 50 μl 
20 μg pTHSN-CD40L DNA                      
5 μl Cutsmart buffer 
2 μl SpeI/NdeI 
 
pAd5∆24  
MQ to 100 μl 
10 μg pAd5∆24 DNA 
10 μl Cutsmart buffer 
2 μl EcoRI 
 
Dephosphorylation 
Dilute the CIP enzyme 1:10 with MQ for 10 ul CIP-diluted 
1 ul CIP-diluted 
5 ul 10X Cutsmart buffer 
The EcoRI digested sample 
 
Restriction analysis 
MQ to 50 ul 
3 ug DNA /5 ul DNA 
5 ul 10x Cutsmart buffer 
1 ul PacI/HindIII/BamHI 
 
Digestion of PCR samples 
MQ to 30 ul 
10 ul PCR sample 
2 ul 10X Cutsmart Buffer 
2 ul HindIII 
 
The digestions were incubated at 37°C for 1-2 hour and separated on a 0.8% agarose or 
0.6% (PacI) gel at 70 volts for 1 hour. 
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APPENDIX 6: NucleoBond® Xtra plasmid purification 
The plasmid purification instructions for the NucleoBond® Xtra kit (Macherey-Nagel, 
cat no: 740410.50). 
 
1 Preparation of starter culture 
Inoculate a 3–5 mL starter culture of LB medium with a single colony picked from a 
freshly streaked agar plate. Make sure that plate and liquid culture contain the appropriate 
selective antibiotic to guarantee plasmid propagation (see section 4.3 for more 
information). Shake at 37 °C and ~ 300 rpm for ~ 8 h. 
 
2 Preparation of large overnight culture 
Note: To utilize the entire large binding capacity of the NucleoBond® Xtra Columns it is 
important to provide enough plasmid DNA. If the culture is known to grow poorly or the 
plasmid does not quite behave like a high-copy plasmid, please consult section 4.6 for 
larger culture volumes. If you are not sure about the plasmid copy number and growth 
behavior of your host strain, increase the culture volume and decide later in step 3 how 
much cells to use for the preparation. The recommended culture volumes below are 
calculated for a final OD600 of around 4 (see section 4.5). 
 
Inoculate an overnight culture by diluting the starter culture 1 / 1000 into the given 
volumes of LB medium also containing the appropriate selective antibiotic. Grow the 
culture overnight at 37 °C and ~ 300 rpm for 12–16 h. 
 
Midi Volume: 100 mL 
3 Harvest of bacterial cells 
Measure the cell culture OD600 and determine the recommended culture volume. 
V [mL] = 400 / OD600 
Pellet the cells by centrifugation at 4,500–6,000 x g for ≥ 10 min at 4 °C and discard the 
supernatant completely. 
 
4 Resuspension (Buffer RES) 
Resuspend the cell pellet completely in 8 mL Resuspension Buffer RES + RNase A by 
pipetting the cells up and down or vortexing the cells. For an efficient cell lysis it is 
important that no clumps remain in the suspension. 
Note: Increase RES buffer volume proportionally if more than the recommended cell 
mass is used (see section 4.8 for information on optimal cell lysis and section 4.9 
regarding difficult-to-lyse strains). 
 
5 Cell lysis (Buffer LYS) 
Add 8 mL Lysis Buffer LYS to the suspension. Mix gently by inverting the tube 5 times. 
Do not vortex as this will shear and release contaminating chromosomal DNA from 
cellular debris into the suspension. Incubate the mixture at room temperature (18–25 °C) 
for 5 min. 
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Warning: Prolonged exposure to alkaline conditions can irreversibly denature and 
degrade plasmid DNA and liberate contaminating chromosomal DNA into the lysate. 
Note: Increase LYS buffer volume proportionally if more than the recommended cell mass 
is used (see section 4.8 for information on optimal cell lysis). 
 
6 Equilibration (Buffer EQU) 
Equilibrate a NucleoBond® Xtra Column together with the inserted column filter with 12 
mL Equilibration Buffer EQU. Apply the buffer onto the rim of the column filter as 
shown in the picture and make sure to wet the entire filter. Allow the column to empty by 
gravity flow. The column does not run dry. 
 
7 Neutralization (Buffer NEU) 
Add 8 mL Neutralization Buffer NEU to the suspension and immediately mix the lysate 
gently by inverting the tube until blue samples turns colorless completely! Do not 
vortex. The flask or tube used for this step should not be filled more than two thirds to 
allow homogeneous mixing. Make sure to neutralize completely to precipitate all the 
protein and chromosomal DNA. The lysate should turn from a slimy, viscous consistency 
to a low viscosity, homogeneous suspension of an off-white flocculate. In addition, 
LyseControl should turn completely colorless without any traces of blue. Immediately 
proceed with step 8. An incubation of the lysate is not necessary. 
Note: Increase NEU buffer volume proportionally if more than the recommended cell 
mass is used (see section 4.8 for information on optimal cell lysis). 
 
8 Clarification and loading 
Make sure to have a homogeneous suspension of the precipitate by inverting the tube 3 
times directly before applying the lysate to the equilibrated NucleoBond® Xtra Column 
Filter to avoid clogging of the filter. The lysate is simultaneously cleared and loaded onto 
the column. Refill the filter if more lysate has to be loaded than the filter is able to hold. 
Allow the column to empty by gravity flow.  
 
Alternative: The precipitate can be removed by centrifugation at ≥ 5,000 x g for at least 
10 min, for example if more than double the recommended cell mass was used. If the 
supernatant still contains suspended matter transfer it to a new tube and repeat the 
centrifugation, preferably at higher speed, or apply the lysate to the equilibrated 
NucleoBond® Xtra Column Filter. This clarification step is extremely important since 
residual precipitate may clog the NucleoBond® Xtra Column. To load the column you 
can either apply the cleared lysate to the equilibrated filter or remove the unused filter 
beforehand. Allow the column to empty by gravity flow. 
 
Note: You may want to save all or part of the flow-through for analysis (see section 
8.1). 
 
9 1st Wash: Column filter and column (Buffer EQU) 
Wash the NucleoBond® Xtra Column Filter and NucleoBond® Xtra Column with 5 mL 
Equilibration Buffer EQU. Apply the buffer to the funnel shaped rim of the filter and 
make sure it is washing out the lysate which is remaining in the filter. Omitting this step 
or just pouring the buffer directly inside the funnel may reduce plasmid yield. 
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10 Filter removal 
Either pull out the NucleoBond® Xtra Column Filter or discard it by turning the column 
upside down. 
 
11 2st Wash: Column only (Buffer WASH) 
Wash the NucleoBond® Xtra Column with 8 mL Wash Buffer WASH. It is important 
to remove the column filter before applying the washing buffer to avoid low purity. 
 
12 Elution (Buffer ELU) 
Elute the plasmid DNA with 5 mL Elution Buffer ELU. Collect the eluate in a 15 mL 
or 50 mL centrifuge tube (not provided). 
Note: Preheating Buffer ELU to 50 °C prior to elution may improve yields for large 
constructs such as BACs. 
 
13 Precipitation 
Add 3.5 mL room-temperature isopropanol to precipitate the eluted plasmid DNA. 
Vortex thoroughly! Centrifuge at ≥ 4,500 x g for ≥ 15 min at ≤ room temperature, 
preferably at 15,000 x g for 30 min at 4 °C. Carefully discard the supernatant. 
 
14 Washing and drying 
Add 2 mL room-temperature 70 % ethanol to the pellet. Centrifuge at ≥ 4,500 x g, 
preferably ≥ 15,000 x g for 5 min at room temperature (18–25 °C). 
Carefully remove ethanol completely from the tube with a pipette tip. Allow the 
pellet to dry at room temperature (18–25 °C) 10–15 min. 
 
15 Reconstitution 
Dissolve the DNA pellet in an appropriate volume of buffer TE or sterile H2O. Depending 
on the type of centrifugation tube, dissolve under gentle pipetting up and down or constant 
spinning in a sufficient amount of buffer for 10–60 min (3D-shaker). Determine plasmid 
yield by UV spectrophotometry. Confirm plasmid integrity by agarose gel electrophoresis 
(see section 4.14). 
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APPENDIX 7: Cell Count for ViraPack and QIAGEN® Effectene Reagent Transfection 
 
ViraPack 
Total cells 9.1 * 105/ml 
Alive cells 8.7*105/ml 
Dead cells 4.0 * 104/ml 
Viability 96% 
 
870,000 * 2 = 1,740,000 cells/ml 
250,000 / 1,740,000 = 0.1436 ca 144 μl 
 
144 μl * 6 = 864 μl to 30 ml media  
 
 
QIAGEN® Effectene Reagent 
Live cells 1.1 x 106/ml 
Dead cells 3.0 x 104/ml 
Total 1.1 x 106/ml 
Viabiliy 97% 
 
800,000 / 5 ml 
1,100,00 * 2 (dilution factor) =2,200,000 live cells 
800,000/2,200,000/ml = 364 μl 
 
364 μl * 6 = 2.2 ml cells to 27.8 ml media 
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APPENDIX 8: ViraPack Transfection kit protocol 
 
The protocol for the ViraPack Transfection Kit (Agilent Technologies, cat no: 200488) 
utilized in the first transfection. 
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109 
 
APPENDIX 9: QIAGEN® Effectene Transfection Reagent protocol 
The instruction manual for the QIAGEN® Effectene Transfection Reagent (QIAGEN®, 
cat no: 301425) for use with adherent cells. 
 
 
 
 
 
 
 
 
 
 
Gibson Plasmid 1: 148.4 μl buffer EC + 1.5 μl DNA 
Gibson Plasmid 2.1: 132 μl buffer EC + 18 μl DNA 
GFP: 1:10 147.2 μl buffer EC + 2.7 μl DNA 
pAd5Δ24: 144.6 μl buffer EC + 5.4 μl DNA 
pAd5/3Δ24: 147.4 μl buffer EC + 2.6 μl DNA 
 
8 μl enhancer to all except Gibson Plasmid 2.1 where 2 μl was added.  
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APPENDIX 10: The Primer Set Testing for colony PCR 
 
The initial testing of the four primer sets intended for colony PCR. The primers were used 
with 0.01 μg DNA of each control together with the Phusion HF polymerase. The samples 
were run on a 2% agarose gel. 
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APPENDIX 11: Colony PCR Results for the mCD40L  
 
The results from the first attempt at homologous recombination displaying the mouse 
CD40L transformed bacterial colonies, ten with mCD40L-FL and ten with mCD40L-S. 
The same colonies were analyzed with two different primer sets, Primer Set I and II. 
Those colonies providing a signal with both sets were regarded as potential positives and 
subsequently underwent plasmid isolation and purification.  
 
Full-length mCD40L 
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Soluble mCD40L  
                            
 
 
 
 
 
 
 
 
